Cronos (CRON) 10-Q 9 Aug 22 2022 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2022	Aug. 05, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-38403
Entity Registrant Name	CRONOS GROUP INC.
Entity Incorporation, State or Country Code	Z4
Entity Address, Address Line One	111 Peter St. Suite 300
Entity Address, City or Town	Toronto
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	M5V 2H1
City Area Code	416
Local Phone Number	504-0004
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	CRON
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		377,896,371
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001656472
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 789,543	$ 886,973
Short-term investments	155,352	117,684
Accounts receivable, net	19,375	22,067
Other receivables	2,175	5,765
Current portion of loans receivable, net	7,613	5,460
Inventory, net	39,842	32,802
Prepaids and other current assets	12,150	8,967
Total current assets	1,026,050	1,079,718
Equity method investments, net	21,731	16,764
Other investments	108,669	118,392
Non-current portion of loans receivable, net	78,436	80,635
Property, plant and equipment, net	66,316	74,070
Right-of-use assets	6,113	8,882
Goodwill	1,087	1,098
Intangible assets, net	23,722	18,079
Other	89	100
Total assets	1,332,213	1,397,738
Current liabilities
Accounts payable	12,449	11,218
Accrued liabilities	23,905	26,069
Current portion of lease obligation	2,267	2,711
Derivative liabilities	574	14,375
Total current liabilities	39,195	54,373
Due to non-controlling interests	1,356	1,913
Non-current portion of lease obligation	6,653	7,095
Deferred income tax liability	46	81
Total liabilities	47,250	63,462
Shareholders’ equity
Share capital (authorized for issue as of June 30, 2022 and December 31, 2021: unlimited; shares outstanding as of June 30, 2022 and December 31, 2021: 377,896,371 and 374,952,693, respectively)	604,626	595,497
Additional paid-in capital	35,198	32,465
Retained earnings	606,557	659,416
Accumulated other comprehensive income	41,688	49,865
Total equity attributable to shareholders of Cronos Group	1,288,069	1,337,243
Non-controlling interests	(3,106)	(2,967)
Total shareholders’ equity	1,284,963	1,334,276
Total liabilities and shareholders’ equity	$ 1,332,213	$ 1,397,738

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, shares issued (in shares)	377,896,371	374,952,693
Common stock, shares outstanding (in shares)	377,896,371	374,952,693

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Loss and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Net revenue, before excise taxes	$ 28,554	$ 18,848	$ 57,960	$ 33,502
Excise taxes	(5,493)	(3,226)	(9,866)	(5,269)
Net revenue	23,061	15,622	48,094	28,233
Cost of sales	18,941	19,445	37,048	35,019
Inventory write-down	0	11,961	0	11,961
Gross profit	4,120	(15,784)	11,046	(18,747)
Operating expenses
Sales and marketing	5,582	13,209	10,594	23,463
Research and development	4,302	5,199	8,341	10,301
General and administrative	17,005	22,417	39,373	44,323
Restructuring costs	1,270	0	4,354	0
Share-based compensation	2,616	2,565	6,302	5,064
Depreciation and amortization	1,411	1,043	2,704	1,778
Impairment loss on goodwill and indefinite-lived intangible assets	0	234,914	0	234,914
Impairment loss on long-lived assets	0	1,214	3,493	2,955
Total operating expenses	32,186	280,561	75,161	322,798
Operating loss	(28,066)	(296,345)	(64,115)	(341,545)
Other income
Interest income, net	3,775	2,293	5,821	4,622
Gain (loss) on revaluation of derivative liabilities	3,410	115,248	13,829	(1,626)
Share of income (loss) from equity method investments	5,197	(1,115)	5,197	(2,758)
Gain (loss) on revaluation of financial instruments	(2,112)	77	2,156	(123)
Impairment loss on other investments	0	0	(11,238)	0
Foreign currency transaction loss	(2,852)	0	(4,724)	0
Other, net	2	1,050	137	1,034
Total other income	7,420	117,553	11,178	1,149
Loss before income taxes	(20,646)	(178,792)	(52,937)	(340,396)
Income tax expense (benefit)	(308)	0	54	0
Loss from continuing operations	(20,338)	(178,792)	(52,991)	(340,396)
Loss from discontinued operations	0	(561)	0	(582)
Net loss	(20,338)	(179,353)	(52,991)	(340,978)
Net loss attributable to non-controlling interest	(117)	(279)	(132)	(592)
Net loss attributable to Cronos Group	(20,221)	(179,074)	(52,859)	(340,386)
Comprehensive loss
Net loss	(20,338)	(179,353)	(52,991)	(340,978)
Other comprehensive income (loss)
Foreign exchange gain (loss) on translation	(24,161)	13,470	(8,184)	29,754
Comprehensive loss	(44,499)	(165,883)	(61,175)	(311,224)
Comprehensive income (loss) attributable to non-controlling interests	122	(394)	(139)	432
Comprehensive loss attributable to Cronos Group	$ (44,621)	$ (165,489)	$ (61,036)	$ (311,656)
Net loss from continuing operations per share
Basic - continuing operations (in dollars per share)	$ (0.05)	$ (0.48)	$ (0.14)	$ (0.92)
Diluted - continuing operations (in dollars per share)	$ (0.05)	$ (0.48)	$ (0.14)	$ (0.92)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total	Share capital	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)	Non-controlling interests
Beginning balance (in shares) at Dec. 31, 2020		360,253,332
Beginning balance at Dec. 31, 2020	$ 1,708,168	$ 569,260	$ 34,596	$ 1,064,509	$ 42,999	$ (3,196)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		11,403,258
Activities relating to share-based compensation	5,452	$ 15,652	(2,506)	(7,694)
Net loss	(161,625)			(161,312)		(313)
Foreign exchange gain (loss) on translation	16,284				15,145	1,139
Ending balance (in shares) at Mar. 31, 2021		371,656,590
Ending balance at Mar. 31, 2021	1,568,279	$ 584,912	32,090	895,503	58,144	(2,370)
Beginning balance (in shares) at Dec. 31, 2020		360,253,332
Beginning balance at Dec. 31, 2020	1,708,168	$ 569,260	34,596	1,064,509	42,999	(3,196)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(340,978)
Foreign exchange gain (loss) on translation	29,754
Ending balance (in shares) at Jun. 30, 2021		371,805,547
Ending balance at Jun. 30, 2021	1,393,784	$ 572,858	32,368	719,593	71,729	(2,764)
Beginning balance (in shares) at Mar. 31, 2021		371,656,590
Beginning balance at Mar. 31, 2021	1,568,279	$ 584,912	32,090	895,503	58,144	(2,370)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		148,957
Activities relating to share-based compensation	2,666	$ 2,451	278	(63)
Top-up rights out-of-period adjustment	(11,278)	$ (14,505)		3,227
Net loss	(179,353)			(179,074)		(279)
Foreign exchange gain (loss) on translation	13,470				13,585	(115)
Ending balance (in shares) at Jun. 30, 2021		371,805,547
Ending balance at Jun. 30, 2021	$ 1,393,784	$ 572,858	32,368	719,593	71,729	(2,764)
Beginning balance (in shares) at Dec. 31, 2021	374,952,693	374,952,693
Beginning balance at Dec. 31, 2021	$ 1,334,276	$ 595,497	32,465	659,416	49,865	(2,967)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		347,287
Activities relating to share-based compensation	3,771	$ 871	2,900
Net loss	(32,653)			(32,638)		(15)
Foreign exchange gain (loss) on translation	15,977				16,223	(246)
Ending balance (in shares) at Mar. 31, 2022		375,299,980
Ending balance at Mar. 31, 2022	$ 1,321,371	$ 596,368	35,365	626,778	66,088	(3,228)
Beginning balance (in shares) at Dec. 31, 2021	374,952,693	374,952,693
Beginning balance at Dec. 31, 2021	$ 1,334,276	$ 595,497	32,465	659,416	49,865	(2,967)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(52,991)
Foreign exchange gain (loss) on translation	$ (8,184)
Ending balance (in shares) at Jun. 30, 2022	377,896,371	377,896,371
Ending balance at Jun. 30, 2022	$ 1,284,963	$ 604,626	35,198	606,557	41,688	(3,106)
Beginning balance (in shares) at Mar. 31, 2022		375,299,980
Beginning balance at Mar. 31, 2022	1,321,371	$ 596,368	35,365	626,778	66,088	(3,228)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		395,156
Activities relating to share-based compensation	2,084	$ 2,251	(167)
Share issuance pursuant to research and development milestones (in shares)		2,201,235
Share issuance pursuant to research and development milestones	6,007	$ 6,007
Net loss	(20,338)			(20,221)		(117)
Foreign exchange gain (loss) on translation	$ (24,161)				(24,400)	239
Ending balance (in shares) at Jun. 30, 2022	377,896,371	377,896,371
Ending balance at Jun. 30, 2022	$ 1,284,963	$ 604,626	$ 35,198	$ 606,557	$ 41,688	$ (3,106)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating activities
Net loss	$ (20,338)	$ (179,353)	$ (52,991)	$ (340,978)
Adjustments to reconcile net loss to cash used in operating activities:
Share-based compensation			6,302	5,064
Depreciation and amortization	4,227	3,203	7,051	5,083
Impairment loss on goodwill and indefinite-lived intangible assets	0	234,914	0	234,914
Impairment loss on long-lived assets	0	1,214	3,493	2,955
Impairment loss on other investments	0	0	11,238	0
(Income) loss from investments			(7,193)	2,758
(Gain) loss on revaluation of derivative liabilities	(3,410)	(115,248)	(13,829)	1,626
Changes in expected credit losses on long-term financial assets			(655)	0
Foreign currency transaction loss	2,852	0	4,724	0
Other non-cash operating activities, net			(1,956)	(1,192)
Changes in operating assets and liabilities:
Accounts receivable, net			1,981	(2,194)
Other receivables			3,590	6,960
Prepaids and other current assets			(3,759)	1,268
Inventory			(8,145)	10,951
Accounts payable and accrued liabilities			(1,042)	(13,412)
Cash flows used in operating activities			(51,191)	(86,197)
Investing activities
Purchase of short-term investments			(157,300)	(120,180)
Proceeds from short-term investments			117,975	136,204
Purchase of other investments			0	(110,392)
(Advances) repayments on loan receivables			1,573	(5,064)
Purchase of property, plant and equipment			(2,218)	(8,347)
Purchase of intangible assets			(421)	(843)
Other investing activities			70	2,059
Cash flows used in investing activities			(40,321)	(106,563)
Financing activities
Withholding taxes paid on share-based awards			(2,080)	(8,919)
Other financing activities, net			46	12
Cash flows used in financing activities			(2,034)	(8,907)
Effect of foreign currency translation on cash and cash equivalents			(3,884)	18,825
Net change in cash and cash equivalents			(97,430)	(182,842)
Cash and cash equivalents, beginning of period			886,973	1,078,023
Cash and cash equivalents, end of period	$ 789,543	$ 895,181	789,543	895,181
Supplemental cash flow information
Interest paid			0	0
Interest received			3,490	2,961
Income taxes paid			$ 140	$ 858

Background, Basis of Presentati

Background, Basis of Presentation and Accounting Policies	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background, Basis of Presentation and Accounting Policies	Background, Basis of Presentation and Accounting Policies (a) Background Cronos Group Inc. (“Cronos Group” or the “Company”) is incorporated in the province of British Columbia and under the Business Corporations Act (British Columbia) with principal executive offices at 111 Peter St., Suite 300, Toronto, Ontario, M5V 2H1. The Company’s common shares are currently listed on the Toronto Stock Exchange (“TSX”) and Nasdaq Global Market (“Nasdaq”) under the ticker symbol “CRON.” Cronos Group is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development and is seeking to build an iconic brand portfolio. Cronos Group’s diverse international brand portfolio includes Spinach ® , PEACE NATURALS ® , Lord Jones ® , Happy Dance ® and PEACE+ ® . (b) Basis of presentation The condensed consolidated interim financial statements of Cronos Group are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for any other reporting period. These condensed consolidated interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2021 (the “Annual Report”). Certain prior year amounts have been reclassified to conform to the current year presentation of our condensed consolidated interim financial statements. These reclassifications had no effect on the reported results of operations and ending shareholders’ equity. (c) Segment information Segment reporting is prepared on the same basis that the Company’s chief operating decision maker (the “CODM”) manages the business, makes operating decisions and assesses the Company’s performance. The Company determined that it has the following two reportable segments: U.S. (the “U.S. segment”) and ROW (the “ROW segment”). The U.S. operating segment consists of the manufacture and distribution of U.S. hemp-derived cannabinoid infused products. The ROW operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets . These two segments represent the geographic regions in which the Company operates and the different product offerings within each geographic region. The results of each segment are regularly reviewed by the CODM to assess the performance of the segment and make decisions regarding the allocation of resources using Adjusted EBITDA (as defined below) as the measure of segment profit or loss. Adjusted EBITDA is defined as earnings before interest, tax, depreciation, non-cash items and items that do not reflect management’s assessment of ongoing business performance. (d) Concentration of risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short-term investments, loans receivable, and advances to joint ventures. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to $1,052,494 and $1,118,684 as of June 30, 2022 and December 31, 2021, respectively. An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan and a failure to make contractual payments for a period of greater than 120 days past due. As of June 30, 2022 and December 31, 2021, the Company had $2 and $8, respectively, in expected credit losses that have been recognized on receivables from contracts with customers in the ROW segment. As of June 30, 2022 and December 31, 2021, the Company had $165 and $104, respectively, in expected credit losses that have been recognized on receivables from contracts with customers in the U.S. segment. As of June 30, 2022, the Company assessed that there is a concentration of credit risk, as 70% of the Company’s accounts receivable were due from three customers with an established credit history with the Company. As of December 31, 2021, 88% of the Company’s accounts receivable were due from four customers with an established credit history with the Company. The Company sells products to a limited number of major customers. Major customers are defined as customers that each individually accounted for greater than 10% of the Company’s revenue. During the three months ended June 30, 2022, the Company earned a total net revenue before excise taxes of $12,767 from three major customers in the ROW segment, together accounting for 56% of the Company’s total net revenues before excise taxes. During the three months ended June 30, 2021, the ROW segment earned a total net revenue before excise taxes of $8,497 from three major customers, together accounting for 45% of the Company’s total net revenues before excise taxes. During the six months ended June 30, 2022, the Company earned a total net revenue before excise taxes of $24,690 from three major customers in the ROW segment, together accounting for 51% of the Company’s total net revenue before excise taxes. During the six months ended June 30, 2021, the ROW segment earned a total net revenue before excise taxes of $18,250 from four major customers, together accounting for 54% of the Company’s total net revenues before excise taxes. During the three and six months ended June 30, 2022 and 2021, the U.S. segment had no major customers. (e) Adoption of new accounting pronouncements On January 1, 2022, the Company adopted ASU No. 2020-06, Debt –Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815–40) (“ASU No. 2020-06”). ASU No. 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU No. 2020-06 is part of the Financial Accounting Standards Board’s (“FASB”) simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The adoption of ASU No. 2020-06 did not have an impact on the Company’s condensed consolidated interim financial statements. (f) New accounting pronouncements not yet adopted In March 2022, the FASB issued ASU 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures (“ASU No. 2022-02”). ASU No. 2022-02 eliminates the existing troubled debt restructuring recognition and measurement guidance, and instead aligns the accounting treatment to that of other loan modifications. The amendments enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. ASU No. 2022-02 also requires that entities disclose current-period gross write-offs by year of origination for financing receivables and net investments in leases. ASU No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, and is to be adopted prospectively. The Company does not expect the adoption of ASU No. 2022-02 to have a material impact on its condensed consolidated interim financial statements. In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU No. 2022-03”). ASU No. 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered in measuring fair value. The amendments also require additional disclosures for equity securities subject to contractual sale restrictions. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, and is to be adopted prospectively. The Company does not expect the adoption of ASU No. 2022-03 to have a material impact on its condensed consolidated interim financial statements.

Inventory, net

Inventory, net	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Inventory, net	Inventory, net Inventory, net is comprised of the following items: As of June 30, 2022 As of December 31, 2021 Raw materials $ 7,435 $ 9,211 Work-in-progress 14,548 12,405 Finished goods 16,926 10,778 Supplies and consumables 933 408 Total $ 39,842 $ 32,802

Investments

Investments	6 Months Ended
	Jun. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Investments	Investments (a) Variable interest entities and equity method investments, net A reconciliation of the carrying amount of the investments in equity method investees, net is as follows: Ownership interest As of June 30, 2022 As of December 31, 2021 Cronos Growing Company Inc. (“Cronos GrowCo”) 50% $ 21,731 $ 16,764 NatuEra S.à.r.l. (“Natuera”) 50% — — $ 21,731 $ 16,764 The following is a summary of the Company’s share of net income (loss) from equity method investments: For the three months ended June 30, For the six months ended June 30, 2022 2021 2022 2021 Cronos GrowCo 5,197 (459) $ 5,197 $ (758) Natuera — (656) — (2,000) $ 5,197 $ (1,115) $ 5,197 $ (2,758) (b) Other investments Other investments consist of investments in common shares and options of two companies in the cannabis industry. PharmaCann, Inc. In 2021, the Company purchased an option (the “PharmaCann Option”) to acquire 473,787 shares of Class A Common Stock of PharmaCann Inc. (“PharmaCann”), a vertically integrated cannabis company in the United States, which represented an ownership interest of approximately 10.5% as of December 31, 2021. The PharmaCann Option is classified as an equity security without a readily determinable fair value. The Company has elected to measure the fair value of the PharmaCann Option at cost less impairment, if any, and subsequently adjusted for observable price changes in orderly transactions for the identical or a similar investment of the same issuer. On February 28, 2022, PharmaCann closed the previously announced transaction with LivWell Holdings, Inc. (“LivWell”) pursuant to which PharmaCann acquired LivWell (the “LivWell Transaction”). LivWell is a multi-state cannabis cultivation and retail leader based in Colorado. As a result of the LivWell Transaction, the Company’s ownership percentage in PharmaCann on a fully-diluted basis decreased to approximately 6.4%. The decrease in ownership percentage does not materially affect the Company’s rights under the PharmaCann Option. Cronos Australia Limited The Company owns approximately 10% of the outstanding common shares of Cronos Australia Limited (“Cronos Australia”). The investment is considered an equity security with a readily determinable fair value. Changes in the fair value of the investment are recorded as gain (loss) on revaluation of financial instruments on the condensed consolidated statements of net loss and comprehensive loss. The following table summarizes the Company’s other investments activity: As of April 1, 2022 Unrealized loss Impairment charges Foreign exchange effect As of June 30, 2022 PharmaCann $ 99,154 $ — $ — $ — $ 99,154 Cronos Australia 12,607 (2,200) — (892) 9,515 $ 111,761 $ (2,200) $ — $ (892) $ 108,669 As of January 1, 2022 Unrealized gain Impairment charges Foreign exchange effect As of June 30, 2022 PharmaCann $ 110,392 $ — $ (11,238) $ — $ 99,154 Cronos Australia 8,000 1,996 — (481) 9,515 $ 118,392 $ 1,996 $ (11,238) $ (481) $ 108,669 During the three months ended March 31, 2022, the Company identified indicators of impairment related to the PharmaCann Option and conducted an analysis comparing the PharmaCann Option’s carrying amount to its estimated fair value. The fair value was estimated using a combination of the market and income approaches. Under the income approach, significant inputs used in the discounted cash flow method include discount rate, growth rates, and cash flow projections. As a result of this analysis, the Company recorded a non-cash impairment charge of $11,238, as the difference between the carrying amount of the PharmaCann Option and its estimated fair value in the condensed consolidated statements of net loss and comprehensive loss. During the three and six months ended June 30, 2021, the Company had no gain or loss on revaluation of other investments. As of June 30, 2022 and December 31, 2021, the Company did not hold any additional other investments.

Loans Receivable, net

Loans Receivable, net	6 Months Ended
	Jun. 30, 2022
Receivables [Abstract]
Loans Receivable, net	Loans Receivable, net Loans receivable, net consists of the following: As of June 30, 2022 As of December 31, 2021 GrowCo Facility (i) $ 3,625 $ 3,138 Add: Current portion of accrued interest 3,988 2,322 Total current portion of loans receivable 7,613 5,460 GrowCo Facility (i) 62,310 64,367 Mucci Promissory Note 14,127 14,019 Cannasoul Collaboration Loan (ii) 1,999 2,249 Total long-term portion of loans receivable 78,436 80,635 Total loans receivable, net $ 86,049 $ 86,095 (i) On August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into a senior secured credit agreement for an aggregate principal amount of C$100,000 (the “GrowCo Facility”). In August 2021, the GrowCo Facility was amended to increase the aggregate principal amount available to C$105,000. As of June 30, 2022 and December 31, 2021, Cronos GrowCo had outstanding borrowings of C$102,000 ($79,228) and C$104,000 ($81,598), respectively, from the GrowCo Facility. As of June 30, 2022, Cronos GrowCo had repaid C$2,000 ($1,554) under the terms of the GrowCo Facility. The available borrowing capacity under the GrowCo Facility was C$1,000 ($777) at June 30, 2022 and December 31, 2021. (ii) As of June 30, 2022 and December 31, 2021, Cannasoul Lab Services Ltd. has received ILS 8,297 ($2,376) and ILS 8,297 ($2,664), respectively, from the Cannasoul Collaboration Loan. Expected credit loss allowances on the Company’s long-term financial assets for the three and six months ended June 30, 2022 and 2021 were comprised of the following items: As of April 1, 2022 Increase (decrease) (i) Foreign exchange effect As of June 30, 2022 GrowCo Facility $ 14,354 $ (660) $ (401) $ 13,293 Mucci Promissory Note 93 1 (3) 91 Cannasoul Collaboration Loan 409 4 (36) 377 $ 14,856 $ (655) $ (440) $ 13,761 As of April 1, 2021 Increase (decrease) Foreign exchange effect As of June 30, 2021 GrowCo Facility $ 1,569 $ — $ 21 $ 1,590 Natuera Series A Loan (ii) 1,151 (1,153) 2 — Mucci Promissory Note 274 — 4 278 Cannasoul Collaboration Loan 26 — 13 39 $ 3,020 $ (1,153) $ 40 $ 1,907 As of January 1, 2022 Increase (decrease) (i) Foreign exchange effect As of June 30, 2022 GrowCo Facility $ 14,089 $ (664) $ (132) $ 13,293 Mucci Promissory Note 90 2 (1) 91 Cannasoul Collaboration Loan 415 7 (45) 377 $ 14,594 $ (655) $ (178) $ 13,761 As of January 1, 2021 Increase (decrease) Foreign exchange effect As of June 30, 2021 GrowCo Facility $ 1,546 $ — $ 44 $ 1,590 Natuera Series A Loan (ii) 721 (737) 16 — Mucci Promissory Note 270 — 8 278 Cannasoul Collaboration Loan 26 — 13 39 $ 2,563 $ (737) $ 81 $ 1,907 (i) During both the three and six months ended June 30, 2022, $655 was recorded as a decrease to general and administrative expenses on the condensed consolidated statements of net loss and comprehensive loss as a result of adjustments to our expected credit losses. There were no such adjustments during the three and six months ended June 30, 2021. (ii) On April 1, 2021, the Company and an affiliate of Agroidea, the other joint venture partner of Natuera, converted all advances made to Natuera under the master loan agreement entered into with Natuera on September 27, 2019, plus accrued interest, into equity of Natuera. As a result, the Company decreased its credit loss allowances by $1,153 and $737 for the three and six months ended June 30, 2021, respectively. As of June 30, 2022 and December 31, 2021, loans receivable, net for the Natuera Series A Loan was $nil.

Intangible Assets, net

Intangible Assets, net	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net Intangible assets, net are comprised of the following items as of June 30, 2022 and December 31, 2021: Useful life (in years) As of June 30, 2022 Cost Accumulated amortization Accumulated impairment charges Net Software 5 $ 6,065 $ (2,137) $ (80) $ 3,848 Health Canada licenses 17 8,706 (1,865) (6,841) — Ginkgo exclusive licenses (i) 10 23,655 (865) (4,668) 18,122 Israeli codes (ii) 20 294 (42) — 252 Total definite-lived intangible assets 38,720 (4,909) (11,589) 22,222 Lord Jones ® brand N/A 64,000 — (62,500) 1,500 Total intangible assets $ 102,720 $ (4,909) $ (74,089) $ 23,722 Useful life (in years) As of December 31, 2021 Cost Accumulated amortization Accumulated impairment charges Net Software 5 $ 5,644 $ (1,595) $ (4) $ 4,045 Health Canada licenses 17 8,793 (1,883) (6,910) — Ginkgo exclusive licenses 10 17,330 (335) (4,752) 12,243 Israeli codes (ii) 20 330 (39) — 291 Total definite-lived intangible assets 32,097 (3,852) (11,666) 16,579 Lord Jones ® brand N/A 64,000 — (62,500) 1,500 Trademarks N/A 142 — (142) — Total intangible assets $ 96,239 $ (3,852) $ (74,308) $ 18,079 (i) In June 2022, the Company announced the achievement of the final productivity target in respect of tetrahydrocannabivarin (“THCV”) under its collaboration and license agreement (the “Ginkgo Collaboration Agreement”) with Ginkgo Bioworks Holdings, Inc. (“Ginkgo”). As a result of the achievement of the final productivity target for THCV, the Company issued 2,201,236 common shares at a share price of C$3.47, and made a cash payment of $600, for total consideration of C$8,412 ($6,522) to Ginkgo through the Ginkgo Collaboration Agreement. The definite-lived intangible asset is being amortized using the straight-line method over its estimated useful life of ten years. (ii) The Israeli codes were transferred by non-controlling interests to Cronos Israel in exchange for their equity interests in the Cronos Israel entities. Amortization expense was $606 and $274 for the three months ended June 30, 2022 and 2021, respectively and $1,121 and $443 for the six months ended June 30, 2022 and 2021, respectively . As of June 30, 2022, the estimated future amortization of definite-lived intangible assets is as follows: As of June 30, 2022 Remainder of 2022 (6 months) $ 1,539 2023 3,034 2024 3,016 2025 2,716 2026 2,109 2027 1,924 Thereafter 7,884 $ 22,222 For the three and six months ended June 30, 2021, the Company recorded an impairment charge of $56,500 on its Lord Jones® brand intangible asset. There were no impairment charges on intangible assets for the three and six months ended June 30, 2022.

Derivative Liabilities

Derivative Liabilities	6 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	Derivative LiabilitiesAs of June 30, 2022, Altria Group Inc. (“Altria”) beneficially held 156,573,537 of the Company’s common shares, an approximate 41% ownership interest in the Company (calculated on a non-diluted basis) and one warrant of the Company (the “Altria Warrant”). As summarized in this note, if exercised in full on such date, the exercise of the Altria Warrant would have resulted in Altria holding a total ownership interest in the Company of approximately 52% (calculated on a non-diluted basis). Pursuant to the investor rights agreement between the Company and Altria (the “Investor Rights Agreement”), entered into in connection with the closing of Altria’s investment in the Company (the “Altria Investment”) pursuant to a subscription agreement dated December 7, 2018, the Company granted Altria certain rights, among others, summarized in this note. The summaries below are qualified entirely by the terms and conditions fully set out in the Investor Rights Agreement and the Altria Warrant, as applicable. a. The Altria Warrant entitles the holder, subject to certain qualifications and limitations, to subscribe for and purchase up to an additional 10% of the common shares of Cronos (83,976,971 common shares as of June 30, 2022) at a per share exercise price of C$19.00, which expires on March 8, 2023. b. The Company granted to Altria, subject to certain qualifications and limitations, upon the occurrence of certain issuances of common shares of the Company executed by the Company (including issuances pursuant to the research and development (“R&D”) partnership (the “Ginkgo Strategic Partnership”) with Ginkgo), the right to purchase up to such number of common shares of the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any issuance of shares by the Company (“Pre-emptive Rights”), at the same price per common share of the Company at which the common shares are sold in the relevant issuance; provided that if the consideration paid in connection with any such issuance is non-cash, the price per common share of the Company that would have been received had such common shares been issued for cash consideration will be determined by an independent committee (acting reasonably and in good faith); provided further that the price per common share of the Company to be paid by Altria pursuant to its exercise of its Pre-emptive Rights related to the Ginkgo Strategic Partnership will be C$16.25 per common share. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%. c. In addition to (and without duplication of) the Pre-emptive Rights, the Company granted to Altria, subject to certain qualifications and limitations, the right to subscribe for common shares of the Company issuable in connection with the exercise, conversion or exchange of convertible securities of the Company issued prior to March 8, 2019 or thereafter (excluding any convertible securities of the Company owned by Altria or any of its subsidiaries), a share incentive plan of the Company, the exercise of any right granted by the Company pro rata to all shareholders of the Company to purchase additional common shares and/or securities of the Company, bona fide bank debt, equipment financing or non-equity interim financing transactions that contemplate an equity component or bona fide acquisitions (including acquisitions of assets or rights under a license or otherwise), mergers or similar business combination transactions or joint ventures involving the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any such transactions (“Top-up Rights”). Reconciliation of the Company’s derivative liabilities activity are as follows: As of April 1, 2022 Revaluation gain Exercise of rights Foreign exchange effect As of June 30, 2022 (a) Altria Warrant $ 3,845 $ (3,245) $ — $ (109) $ 491 (b) Pre-emptive Rights 67 (49) — (2) 16 (c) Top-up Rights 187 (116) — (4) 67 $ 4,099 $ (3,410) $ — $ (115) $ 574 As of April 1, 2021 Revaluation gain Out-of-period adjustment Foreign exchange effect As of June 30, 2021 (a) Altria Warrant $ 234,656 $ (85,778) $ — $ 1,205 $ 150,083 (b) Pre-emptive Rights 20,173 (6,360) — 113 13,926 (c) Top-up Rights 17,471 (23,110) 11,278 (85) 5,554 $ 272,300 $ (115,248) $ 11,278 $ 1,233 $ 169,563 As of January 1, 2022 Revaluation gain Exercise of rights Foreign exchange effect As of June 30, 2022 (a) Altria Warrant $ 13,720 $ (13,256) $ — $ 27 $ 491 (b) Pre-emptive Rights 180 (164) — — 16 (c) Top-up Rights 475 (409) — 1 67 $ 14,375 $ (13,829) $ — $ 28 $ 574 As of January 1, 2021 Revaluation (gain)/loss Exercise of rights Foreign exchange effect As of June 30, 2021 (a) Altria Warrant $ 138,858 $ 7,186 $ — $ 4,039 $ 150,083 (b) Pre-emptive Rights 12,095 1,473 — 358 13,926 (c) Top-up Rights 12,457 (7,033) — 130 5,554 $ 163,410 $ 1,626 $ — $ 4,527 $ 169,563 Fluctuations in the Company’s share price and the expected life of the derivative instruments are primary drivers for the changes in the derivative valuations during each reporting period. As the share price decreases and the expected period of time the derivative liability is expected to be outstanding decreases, the fair value typically decreases for each related derivative instrument. Share price and weighted-average expected life are two of the significant observable inputs used in the fair value measurement of each of the Company’s derivative instruments. The fair values of the derivative liabilities were determined using the Black-Scholes pricing model using the following inputs: As of June 30, 2022 Altria Warrant Pre-emptive Rights Top-up Rights Share price at valuation date (per share in C$) $3.60 $3.60 $3.60 Subscription price (per share in C$) $19.00 $16.25 $16.25 Weighted-average risk-free interest rate (i) 2.74% 2.47% 2.51% Weighted-average expected life (in years) (ii) 0.69 0.45 0.63 Expected annualized volatility (iii) 77% 77% 77% Expected dividend yield —% —% —% As of December 31, 2021 Altria Warrant Pre-emptive Rights Top-up Rights Share price at valuation date (per share in C$) $4.98 $4.98 $4.98 Subscription price (per share in C$) $19.00 $16.25 $16.25 Weighted-average risk-free interest rate (i) 0.79% 0.39% 0.50% Weighted-average expected life (in years) (ii) 1.18 0.50 0.80 Expected annualized volatility (iii) 80% 80% 80% Expected dividend yield —% —% —% (i) The risk-free interest rate was based on Bank of Canada government treasury bills and bonds with a remaining term equal to the expected life of the derivative liabilities. As of June 30, 2022 and December 31, 2021, the risk-free interest rate uses a range of approximately 2.06% to 3.09% and 0.16% to 1.10%, respectively, for the Pre-emptive Rights and Top-up Rights. (ii) The expected life represents the period of time, in years, that the derivative liabilities are expected to be outstanding. The expected life of the Pre-emptive Rights and Top-up Rights is determined based on the expected term of the underlying options, warrants, and shares, to which the Pre-emptive Rights and Top-up Rights are linked. As of June 30, 2022 and December 31, 2021, the expected life uses a range of approximately 0.25 years to 3.25 years and 0.25 years to 3.75 years, respectively, for the Pre-emptive Rights and Top-up Rights. (iii) Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company. The following table quantifies each of the significant inputs described above and provides a sensitivity analysis of the impact on the reported values of the derivative liabilities. The sensitivity analysis for each significant input is performed by assuming a 10% decrease in the input while other significant inputs remain constant at management’s best estimate as of the respective dates. While a decrease in the inputs noted below would cause a decrease in the carrying amount of the derivative liability, there would also be an equal and opposite impact on net income (loss). 10% decrease as of June 30, 2022 Altria Warrant Pre-emptive Rights Top-up Rights Share price $ 219 $ 8 $ 19 Weighted-average expected life 196 16 24 Expected annualized volatility 318 11 27 10% decrease as of December 31, 2021 Altria Warrant Pre-emptive Rights Top-up Rights Share price $ 3,970 $ 80 $ 123 Weighted-average expected life 2,971 171 133 Expected annualized volatility 5,402 96 155 These inputs are classified as Level 3 on the fair value hierarchy and are subject to volatility and several factors outside the Company’s control, which could significantly affect the fair value of these derivative liabilities in future periods.

Restructuring

Restructuring	6 Months Ended
	Jun. 30, 2022
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In the first quarter of 2022, the Company initiated a strategic plan to realign the business around its brands, centralize functions and evaluate the Company’s supply chain (the “Realignment”). As part of the Realignment, on February 28, 2022, the Company’s Board of Directors (the “Board”) approved plans to leverage the Company’s strategic partnerships to improve supply chain efficiencies and reduce manufacturing overhead by exiting its production facility in Stayner, Ontario, Canada (the “Stayner Facility”). The Realignment initiatives being undertaken are intended to position the Company to drive profitable and sustainable growth over time. The Company expects to incur approximately $6,400 in connection with the Realignment, including the planned exit of the Stayner Facility, of which $4,354 has been incurred as of June 30, 2022. Estimated charges related to the exit of the Stayner Facility include employee-related costs such as severance, relocation and other termination benefits, as well as contract termination and other related costs. The Company expects to incur approximately $2,000 in additional charges related to the Realignment, including the planned exit of the Stayner Facility. The Company incurred the following restructuring costs by reportable segment: Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Rest of World $ 978 $ — $ 3,009 $ — United States 292 — 1,345 — Total $ 1,270 $ — $ 4,354 $ — The following table summarizes the Company’s restructuring activity for the three and six months ended June 30, 2022: Accrual as of April 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee termination benefits $ 1,254 $ 432 $ (798) $ 888 Other restructuring costs 144 838 (961) 21 Total $ 1,398 $ 1,270 $ (1,759) $ 909 Accrual as of January 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee termination benefits $ — $ 2,935 $ (2,047) $ 888 Other restructuring costs — 1,419 (1,398) 21 Total $ — $ 4,354 $ (3,445) $ 909

Share-based Compensation

Share-based Compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Share-based Compensation	Share-based Compensation (a) Share-based award plans The Company has granted stock options, restricted share units (“RSUs”) and deferred share units (“DSUs”) to employees and non-employee directors under the Stock Option Plan dated May 26, 2015 (the “2015 Stock Option Plan”), the 2018 Stock Option Plan dated June 28, 2018 (the “2018 Stock Option Plan” and, together with the 2015 Stock Option Plan, the “Prior Option Plans”), the Employment Inducement Award Plan #1 (the “Employment Inducement Award Plan”), the 2020 Omnibus Equity Incentive Plan dated March 29, 2020 (the “2020 Omnibus Plan”) and the DSU Plan dated August 10, 2019 (the “DSU Plan”). The Company can no longer make grants under the Prior Option Plans or the Employment Inducement Award Plan. The following table summarizes the total share-based compensation expense associated with the Company’s stock options and RSUs for the three and six months ended June 30, 2022: Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Stock options $ 1,141 $ 1,864 $ 2,870 $ 3,928 RSUs 1,475 701 3,432 1,136 Total share-based compensation $ 2,616 $ 2,565 $ 6,302 $ 5,064 (b) Stock options Vesting conditions for grants of options are determined by the Compensation Committee of the Board. The typical vesting for stock option grants made under the 2020 Omnibus Plan is annual vesting over three three The following is a summary of the changes in stock options for the six months ended June 30, 2022 and 2021: Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2022 $ 7.75 8,939,330 2.70 Exercise of options 3.11 (1,481,004) Cancellation, forfeiture and expiry of options 13.56 (89,251) Balance as of June 30, 2022 $ 8.61 7,369,075 1.53 Exercisable as of June 30, 2022 $ 8.28 4,686,991 1.04 Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2021 $ 5.40 13,755,148 2.30 Exercise of options 2.14 (5,349,818) Cancellation, forfeiture and expiry of options 14.86 (33,699) Balance as of June 30, 2021 $ 7.45 8,371,631 2.66 Exercisable as of June 30, 2021 $ 6.49 4,679,240 1.43 (i) The weighted-average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance. The following table summarizes stock options outstanding: As of June 30, 2022 As of December 31, 2021 2020 Omnibus Plan 2,900,000 2,900,000 2018 Stock Option Plan 1,492,010 1,550,074 2015 Stock Option Plan 2,977,065 4,489,256 Total stock options outstanding 7,369,075 8,939,330 (c) Restricted share units The following is a summary of the changes in RSUs for the six months ended June 30, 2022 and 2021: Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2022 $ 9.22 1,225,870 Granted (i) 4.32 4,513,992 Vested and issued 8.58 (722,721) Cancellation and forfeitures 8.32 (101,561) Balance as of June 30, 2022 $ 4.84 4,915,580 Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2021 $ 7.66 948,357 Granted (i) 11.29 515,433 Vested and issued $ 7.52 (89,912) Balance as of June 30, 2021 $ 9.03 1,373,878 (i) RSUs granted in the period vest annually in equal installments over a three-year period from the grant date or vest after a three (ii) The weighted-average grant date fair value reflects the conversion of foreign currency-denominated RSUs translated into C$ using the foreign exchange rate as of the date of issuance. (d) Deferred share units The following is a summary of the changes in DSUs for the six months ended June 30, 2022 and 2021: Financial liability Number of DSUs Balance as of January 1, 2022 $ 408 104,442 Gain on revaluation (161) — Balance as of June 30, 2022 $ 247 104,442 Financial liability Number of DSUs Balance as of January 1, 2021 $ 577 83,293 Loss on revaluation 141 — Balance as of June 30, 2021 $ 718 83,293 (e) Warrants The following is a summary of the changes in warrants for the six months ended June 30, 2021: Weighted-average exercise price (C$) Number of warrants Balance as of January 1, 2021 $ 0.25 7,987,349 Exercise of warrants 0.25 (7,987,349) Balance as of June 30, 2021 $ — — As of June 30, 2022, there are no warrants outstanding other than the Altria Warrant. See Note 6 “ Derivative Liabilities ” for further description of the Altria Warrant.

Earnings (Loss) per Share

Earnings (Loss) per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	Earnings (Loss) per Share Basic and diluted earnings (loss) per share from continuing and discontinued operations are calculated as follows (in thousands, except share and per share amounts): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Basic and diluted earnings (loss) per share computation Net loss from continuing operations attributable to the shareholders of Cronos Group $ (20,221) $ (178,513) $ (52,859) $ (339,804) Weighted-average number of common shares outstanding for computation for basic and diluted earnings per share (i) 376,031,860 371,721,382 375,530,077 367,391,118 Basic loss from continuing operations per share $ (0.05) $ (0.48) $ (0.14) $ (0.92) Diluted loss per share from continuing operations $ (0.05) $ (0.48) $ (0.14) $ (0.92) Loss from discontinued operations attributable to the shareholders of Cronos Group $ — $ (561) $ — $ (582) Weighted-average number of common shares outstanding from computation for basic and diluted earnings per share 376,031,860 371,721,382 375,530,077 367,391,118 Basic earnings (loss) from discontinued operations per share $ 0.00 $ 0.00 $ 0.00 $ 0.00 Diluted earnings (loss) from discontinued operations per share $ 0.00 $ 0.00 $ 0.00 $ 0.00 (i) In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported as the inclusion of the common share equivalents would be anti-dilutive. For the three months ended June 30, 2022 and 2021, total securities of 119,589,123 and 120,491,183, respectively, and for the six months ended June 30, 2022 and 2021, total securities of 118,906,603 and 128,373,444, respectively, were not included in the computation of diluted shares outstanding, because the effect would be anti-dilutive.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Segment Information	Segment Information The tables below set forth our condensed consolidated results of operations by segment. The Company’s condensed consolidated financial results for these periods are not necessarily indicative of the consolidated financial results that the Company will achieve in future periods . Segment data was as follows for the three and six months ended June 30, 2022 and 2021: Three months ended June 30, 2022 United States Rest of World Corporate Total Cannabis flower $ — $ 15,739 $ — $ 15,739 Cannabis extracts 1,459 5,582 — 7,041 Other — 281 — 281 Net revenue $ 1,459 $ 21,602 $ — $ 23,061 Share of income from equity method investments $ — $ 5,197 $ — $ 5,197 Total assets $ 430,455 $ 285,902 $ 615,856 $ 1,332,213 Depreciation and amortization $ 87 $ 1,324 $ — $ 1,411 Adjusted EBITDA (3,877) (8,995) (5,927) (18,799) Three months ended June 30, 2021 United States Rest of World Corporate Total Cannabis flower $ — $ 11,597 $ — $ 11,597 Cannabis extracts 2,227 1,531 — 3,758 Other — 267 — 267 Net revenue $ 2,227 $ 13,395 $ — $ 15,622 Share of loss from equity method investments $ — $ (1,115) $ — $ (1,115) Total assets $ 473,828 $ 386,805 $ 741,850 $ 1,602,483 Depreciation and amortization 68 975 — 1,043 Adjusted EBITDA (10,711) (32,605) (6,443) (49,759) Six months ended June 30, 2022 United States Rest of World Corporate Total Cannabis flower $ — $ 34,364 $ — $ 34,364 Cannabis extracts 3,787 9,570 — 13,357 Other — 373 — 373 Net revenue $ 3,787 $ 44,307 $ — $ 48,094 Share of income from equity method investments $ — $ 5,197 $ — $ 5,197 Total assets $ 430,455 $ 285,902 $ 615,856 $ 1,332,213 Depreciation and amortization 183 2,521 — 2,704 Adjusted EBITDA (10,963) (12,420) (14,316) (37,699) Six months ended June 30, 2021 United States Rest of World Corporate Total Cannabis flower $ — $ 21,031 $ — $ 21,031 Cannabis extracts 4,668 2,234 — 6,902 Other — 300 — 300 Net revenue $ 4,668 $ 23,565 $ — $ 28,233 Share of loss from equity method investments $ — $ (2,758) $ — $ (2,758) Total assets $ 473,828 $ 386,805 $ 741,850 $ 1,602,483 Depreciation and amortization 139 1,639 — 1,778 Adjusted EBITDA (20,221) (54,789) (11,323) (86,333) The following tables set forth a reconciliation of net income (loss) as determined in accordance with U.S. GAAP to Adjusted EBITDA for the periods indicated: Three months ended June 30, 2022 United States Rest of World Corporate Total Net loss $ (4,498) $ (8,759) $ (7,081) $ (20,338) Interest income, net (426) (3,349) — (3,775) Income tax benefit — (308) — (308) Share of income from equity method investments — (5,197) — (5,197) Gain on revaluation of derivative liabilities (iii) — (3,410) — (3,410) Loss on revaluation of financial instruments (v) — 2,112 — 2,112 Foreign currency transaction loss — 2,852 — 2,852 Other, net (vii) — (2) — (2) Restructuring costs (ix) 292 978 — 1,270 Share-based compensation (x) 473 2,143 — 2,616 Financial statement review costs (xi) — — 1,154 1,154 Depreciation and amortization 282 3,945 — 4,227 Adjusted EBITDA $ (3,877) $ (8,995) $ (5,927) $ (18,799) Three months ended June 30, 2021 United States Rest of World Corporate Total Net income (loss) $ (247,847) $ 79,627 $ (11,133) $ (179,353) Interest income, net (20) (2,273) — (2,293) Share of loss from equity method investments — 1,115 — 1,115 Impairment loss on goodwill and indefinite-lived intangible assets (i) 234,914 — — 234,914 Impairment loss on long-lived assets (ii) 1,214 — — 1,214 Gain on revaluation of derivative liabilities (iii) — (115,248) — (115,248) Transaction costs (iv) — — 2,758 2,758 Gain on revaluation of financial instruments (v) — (77) — (77) Other, net (vii) — (1,050) — (1,050) Loss from discontinued operations (viii) — 561 — 561 Share-based compensation (x) 822 1,743 — 2,565 Financial statement review costs (xi) — — 1,932 1,932 Depreciation and amortization 206 2,997 — 3,203 Adjusted EBITDA $ (10,711) $ (32,605) $ (6,443) $ (49,759) Six months ended June 30, 2022 United States Rest of World Corporate Total Net loss $ (26,714) $ (6,745) $ (19,532) $ (52,991) Interest income, net (455) (5,366) — (5,821) Income tax expense — 54 — 54 Share of income from equity method investments — (5,197) — (5,197) Impairment loss on long-lived assets (ii) — 3,493 — 3,493 Gain on revaluation of derivative liabilities (iii) — (13,829) — (13,829) Gain on revaluation of financial instruments (v) — (2,156) — (2,156) Impairment loss on other investment (vi) 11,238 — — 11,238 Foreign currency transaction loss — 4,724 — 4,724 Other, net (vii) — (137) — (137) Restructuring costs (ix) 1,345 3,009 — 4,354 Share-based compensation (x) 2,909 3,393 — 6,302 Financial statement review costs (xi) — — 5,216 5,216 Depreciation and amortization 714 6,337 — 7,051 Adjusted EBITDA $ (10,963) $ (12,420) $ (14,316) $ (37,699) Six months ended June 30, 2021 United States Rest of World Corporate Total Net loss $ (259,939) $ (62,520) $ (18,519) $ (340,978) Interest income, net (23) (4,599) — (4,622) Share of loss from equity method investments — 2,758 — 2,758 Impairment loss on goodwill and indefinite-lived intangible assets (i) 234,914 — — 234,914 Impairment loss on long-lived assets (ii) 2,955 — — 2,955 Loss on revaluation of derivative liabilities (iii) — 1,626 — 1,626 Transaction costs (iv) — — 3,259 3,259 Loss on revaluation of financial instruments (v) — 123 — 123 Other, net (vii) — (1,034) — (1,034) Loss from discontinued operations (viii) — 582 — 582 Share-based compensation (x) 1,567 3,497 — 5,064 Financial statement review costs (xi) — — 3,937 3,937 Depreciation and amortization 305 4,778 — 5,083 Adjusted EBITDA $ (20,221) $ (54,789) $ (11,323) $ (86,333) (i) For the three and six months ended June 30, 2021, impairment on goodwill and indefinite-lived intangible assets relates to impairment on goodwill and indefinite-lived intangible assets related to the Company’s U.S. segment. (ii) For the six months ended June 30, 2022, impairment loss on long-lived assets related to the Company’s decision to seek a sublease for leased office space in Toronto, Ontario, Canada during the first quarter of 2022. For the three months ended June 30, 2021, impairment loss on long-lived assets relates to an impairment on property, plant and equipment in the U.S. segment. For the six months ended June 30, 2021, impairment loss on long-lived assets relates to the aforementioned impairment loss on property, plant and equipment as well as an impairment loss on leased premises in the U.S. segment from the first quarter of 2021. See Note 13 “ Impairment Loss on Long-lived Assets .” (iii) For the three and six months ended June 30, 2022 and 2021, (gain) loss on revaluation of derivative liabilities represents the fair value changes on the derivative liabilities. See Note 6 “ Derivative Liabilities .” (iv) For the three and six months ended June 30, 2021, transaction costs represent legal, financial and other advisory fees and expenses incurred in connection with various strategic investments. These costs are included in general and administrative expenses on the condensed consolidated statements of net income (loss) and comprehensive income (loss). (v) For the three and six months ended June 30, 2022, (gain) loss on revaluation of financial instruments related primarily to the Company’s equity securities in Cronos Australia. For three and six months ended June 30, 2021, (gain) loss on revaluation of financial instruments related primarily to revaluations of financial liabilities resulting from DSUs. (vi) For the six months ended June 30, 2022, impairment loss on other investments related to the PharmaCann Option for the difference between its fair value and carrying amount. See Note 3 “ Investments. ” (vii) For the three and six months ended June 30, 2022, other, net related to (gain) loss on disposal of assets. For the three and six months ended June 30, 2021, other, net primarily related to gain recorded on sale of the Company’s Winnipeg facility previously designated as held-for-sale in the first quarter of 2021. (viii) For the three and six months ended June 30, 2021, loss from discontinued operations related to the discontinuance of Original B.C. Ltd. (“OGBC”). (ix) For the three and six months ended June 30, 2022, restructuring costs related to the employee-related severance costs and other restructuring costs associated with the Realignment, including the planned exit of the Stayner Facility. See Note 7 “ Restructuring. ” (x) For the three and six months ended June 30, 2022 and 2021, share-based compensation related to the vesting expenses of share-based compensation awarded to employees under the Company’s share-based award plans as described in Note 8 “ Share-based Compensation .” (xi) For the three and six months ended June 30, 2022 and 2021, financial statement review costs include costs and reserves taken related to the restatements of the Company’s 2019 and second quarter 2021 interim financial statements, costs related to the Company’s responses to requests for information from various regulatory authorities relating to such restatements and legal costs defending shareholder class action complaints brought against the Company as a result of the 2019 restatement. Net revenue attributed to a geographic region based on the location of the customer were as follows: Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Canada $ 14,388 $ 10,664 $ 27,965 $ 18,246 Israel 7,214 2,310 16,342 4,828 United States 1,459 2,227 3,787 4,668 Other countries — 421 — 491 Net revenue $ 23,061 $ 15,622 $ 48,094 $ 28,233

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Loss Contingency [Abstract]
Commitments and Contingencies	Commitments and Contingencies (a) Commitments There have been no material changes in the information regarding commitments as disclosed in the Company’s Annual Report. (b) Contingencies The Company is subject to various legal proceedings in the ordinary course of its business and in connection with its marketing, distribution and sale of its products. Many of these legal proceedings are in the early stages of litigation and seek damages that are unspecified or not quantified. Although the outcome of these matters cannot be predicted with certainty, the Company does not believe these legal proceedings, individually or in the aggregate, will have a material adverse effect on its financial condition but could be material to its results of operations for a quarterly period depending, in part, on its results for that quarter. (i) Class action complaints relating to restatement of 2019 interim financial statements On March 11 and 12, 2020, two alleged shareholders of the Company separately filed two putative class action complaints in the U.S. District Court for the Eastern District of New York against the Company and its Chief Executive Officer and now former Chief Financial Officer. The court has consolidated the cases, and the consolidated amended complaint alleges violations of Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder against all defendants, and Section 20(a) of the Exchange Act against the individual defendants. The consolidated amended complaint generally alleges that certain of the Company’s prior public statements about revenues and internal control were incorrect based on the Company’s disclosures relating to the Audit Committee of the Board’s review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel. The consolidated amended complaint does not quantify a damage request. Defendants moved to dismiss on February 8, 2021. On June 3, 2020, an alleged shareholder filed a Statement of Claim, as amended on August 12, 2020, in the Ontario Superior Court of Justice in Toronto, Ontario, Canada, seeking, among other things, an order certifying the action as a class action on behalf of a putative class of shareholders and damages of an unspecified amount. The Amended Statement of Claim names (i) the Company, (ii) its Chief Executive Officer, (iii) now former Chief Financial Officer, (iv) former Chief Financial Officer and Chief Commercial Officer, and (v) current and former members of the Board as defendants and alleges breaches of the Ontario Securities Act, oppression under the Ontario Business Corporations Act and common law misrepresentation. The Amended Statement of Claim generally alleges that certain of the Company’s prior public statements about revenues and internal control were misrepresentations based on the Company’s March 2, 2020 disclosure that the Audit Committee of the Board was conducting a review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel, and the Company’s subsequent restatement. The Amended Statement of Claim does not quantify a damage request. On June 28, 2021, the Court dismissed motions brought by the plaintiff for leave to commence a claim for misrepresentation under the Ontario Securities Act and for certification of the action as a class action. The plaintiff has appealed the Court’s dismissal of the motions only with respect to the Company, the Chief Executive Officer, and the now former Chief Financial Officer; the remaining defendants were dismissed from the matter with prejudice, and the Company and all individual defendants agreed not to seek costs from plaintiff in connection with the dismissal of the motions. (ii) Regulatory reviews relating to restatements The Company has been responding to requests for information from various regulatory authorities relating to its previously disclosed restatement of its financial statements for the first three quarters of 2019 as well as the previously disclosed restatement of the second quarter of 2021 interim financial statements. The Company is responding to all such requests for information and cooperating with all regulatory authorities. The Company cannot predict the outcome of any such regulatory review or investigation and it is possible that additional investigations or one or more formal proceedings may be commenced against the Company and its current and former officers and directors in connection with these regulatory reviews and investigations. (iii) Litigation relating to marketing, distribution and sale of products On June 16, 2020, an alleged consumer filed a Statement of Claim on behalf of a class in the Court of Queen’s Bench of Alberta in Alberta, Canada, against the Company and other Canadian cannabis manufacturers and/or distributors. On December 4, 2020, a Third Amended Statement of Claim was filed, which added a second alleged consumer. The Third Amended Statement of Claim alleges claims related to the defendants’ advertised content of cannabinoids in cannabis products for medicinal use on or after June 16, 2010 and cannabis products for adult use on or after October 17, 2018. The Third Amended Statement of Claim seeks a total of C$500 million for breach of contract, compensatory damages, and unjust enrichment or such other amount as may be proven in trial and C$5 million in punitive damages against each defendant, including the Company. The Third Amended Statement of Claim also seeks interest and costs associated with the action. The Company has not responded to the Third Amended Statement of Claim. On January 31, 2022, upon consent of the Company and the plaintiffs, the court dismissed the case in its entirety as to the Company. A number of claims, including purported class actions, have been brought in the U.S. against companies engaged in the U.S. hemp business alleging, among other things, violations of state consumer protection, health and advertising laws. On April 8, 2020, a putative class action complaint was filed in the U.S. District Court for the Central District of California against Redwood Holding Group, LLC (“Redwood”), alleging violations of California’s Unfair Competition Law, False Advertising Law, Consumers Legal Remedies Act, and breaches of the California Commercial Code for breach of express warranties and implied warranty of merchantability with respect to Redwood’s marketing and sale of U.S. hemp products. The complaint did not quantify a damage request. On April 10, 2020, the class action complaint was dismissed for certain pleading deficiencies and the plaintiff was granted leave until April 24, 2020 to amend the complaint to establish federal subject matter jurisdiction. On April 28, 2020, the action was dismissed without prejudice for failure to prosecute and for failure to comply with a court order. As of the date of this Quarterly Report, the plaintiff has not refiled the complaint.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Risks and Uncertainties [Abstract]
Fair Value Measurements	Fair Value Measurements The Company complies with ASC 820 Fair Value Measurements for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values are determined by: • Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. • Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability. The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis: June 30, 2022 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 789,543 $ — $ — $ 789,543 Short-term investments 155,352 — — 155,352 Other investments (i) 9,515 — — 9,515 Derivative liabilities — — 574 574 December 31, 2021 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 886,973 $ — $ — $ 886,973 Short-term investments 117,684 — — 117,684 Other investments (i) 8,000 — — 8,000 Derivative liabilities — — 14,375 14,375 (i) As of June 30, 2022 and December 31, 2021, the Company’s influence on Cronos Australia is deemed non-significant and the investment is considered an equity security with a readily determinable fair value. See Note 3 “ Investments ” for additional information. There were no transfers between fair value categories during the periods presented.

Impairment Loss on Long-lived A

Impairment Loss on Long-lived Assets	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment Loss on Long-lived Assets	Impairment Loss on Long-lived Assets (a) Right-of-use assets and property, plant, and equipment, net During the six months ended June 30, 2022, the Company recognized an impairment charge of $1,986 related to the right-of-use lease asset associated with the Company’s corporate headquarters, encompassing approximately 29,000 square feet, in Toronto, Ontario, Canada, for which the Company determined it would seek a sublease. In addition, the Company recognized an impairment charge of $1,507 during the six months ended June 30, 2022 related to leasehold improvements and other office equipment that it plans to include in any potential sublease agreement. The determination to seek a sublease of the property and include leasehold improvements and other office equipment in any potential sublease agreement triggered the impairment charges. Both of the impairment charges are recognized as impairment loss on long-lived assets on the condensed consolidated statements of net loss and comprehensive loss. During the three months ended June 30, 2021, the Company concluded that there were impairment indicators on property, plant and equipment associated with sales channels in the U.S. segment. As a result, a quantitative impairment analysis was required as of June 30, 2021. As such, the Company reassessed its estimates and forecasts as of June 30, 2021, to determine the fair values of the property, plant and equipment using an undiscounted cash flow methodology. Significant inputs include growth rates and cash flow projections. As a result of the analysis, as of June 30, 2021, the Company concluded the carrying amount of the property, plant and equipment associated with sales channels in the U.S. segment exceeded its fair value, which resulted in impairment charges of $1,214 on the condensed consolidated statements of net loss and comprehensive loss for the three and six months ended June 30, 2021. During the six months ended June 30, 2021, the Company recognized an impairment charge of $1,039 related to leasehold improvements located within leased premises, encompassing approximately 6,000 square feet, in Los Angeles, California, which the Company determined it no longer had plans to use. The significant change in the extent and manner in which the leasehold improvements are being used and the expectation that, more likely than not, the leasehold improvements will be disposed of before the end of their useful life triggered an impairment. The right-of-use lease asset associated with the leasehold improvements was also written down as a result of the Company’s decision to no longer use the leased premises. The Company recognized an impairment charge on the de-recognition of the right-of-use asset of $702 during the six months ended June 30, 2021. Both of the impairment charges are recognized as impairment loss on long-lived assets on the condensed consolidated statements of net loss and comprehensive loss. No impairment charges were recorded during the three months ended June 30, 2022 on property, plant and equipment and right-of-use assets, other than as noted above.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions (a) Altria On March 8, 2019, in connection with the Altria Investment, Altria, through certain of its wholly owned subsidiaries, purchased a 45% equity interest in the Company. As of June 30, 2022, Altria beneficially held an approximately 41% ownership interest in the Company (calculated on a non-diluted basis). The Company incurred the following expenses for consulting services from Altria Pinnacle LLC, a subsidiary of Altria (“Altria Pinnacle”): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Altria Pinnacle - expense $ — $ 2 $ 28 $ 12 As of both June 30, 2022 and December 31, 2021, the Company had no payables outstanding to Altria Pinnacle. (b) Cronos GrowCo The Company holds a variable interest in Cronos GrowCo through its ownership of 50% of Cronos GrowCo’s common shares and senior secured debt in Cronos GrowCo. See Note 3 “ Investments ” for additional information. The Company made the following purchases of cannabis products from Cronos GrowCo: Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Cronos GrowCo - purchases $ 5,597 $ 534 $ 8,815 $ 534 As of June 30, 2022 and December 31, 2021, the Company had payables outstanding to Cronos GrowCo of $2,103 and $82, respectively. Additionally, on August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into the GrowCo Facility. See Note 4 “ Loans Receivable, net ” for additional information.

Background, Basis of Presenta_2

Background, Basis of Presentation and Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation The condensed consolidated interim financial statements of Cronos Group are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for any other reporting period. These condensed consolidated interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2021 (the “Annual Report”). Certain prior year amounts have been reclassified to conform to the current year presentation of our condensed consolidated interim financial statements. These reclassifications had no effect on the reported results of operations and ending shareholders’ equity.
Segment information	Segment information Segment reporting is prepared on the same basis that the Company’s chief operating decision maker (the “CODM”) manages the business, makes operating decisions and assesses the Company’s performance. The Company determined that it has the following two reportable segments: U.S. (the “U.S. segment”) and ROW (the “ROW segment”). The U.S. operating segment consists of the manufacture and distribution of U.S. hemp-derived cannabinoid infused products. The ROW operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets . These two segments represent the geographic regions in which the Company operates and the different product offerings within each geographic region. The results of each segment are regularly reviewed by the CODM to assess the performance of the segment and make decisions regarding the allocation of resources using Adjusted EBITDA (as defined below) as the measure of segment profit or loss. Adjusted EBITDA is defined as earnings before interest, tax, depreciation, non-cash items and items that do not reflect management’s assessment of ongoing business performance.
Concentration of risk	Concentration of risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short-term investments, loans receivable, and advances to joint ventures. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to $1,052,494 and $1,118,684 as of June 30, 2022 and December 31, 2021, respectively. An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan and a failure to make contractual payments for a period of greater than 120 days past due. As of June 30, 2022 and December 31, 2021, the Company had $2 and $8, respectively, in expected credit losses that have been recognized on receivables from contracts with customers in the ROW segment. As of June 30, 2022 and December 31, 2021, the Company had $165 and $104, respectively, in expected credit losses that have been recognized on receivables from contracts with customers in the U.S. segment.
Adoption of new accounting pronouncements and New accounting pronouncements not yet adopted	Adoption of new accounting pronouncements On January 1, 2022, the Company adopted ASU No. 2020-06, Debt –Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815–40) (“ASU No. 2020-06”). ASU No. 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU No. 2020-06 is part of the Financial Accounting Standards Board’s (“FASB”) simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The adoption of ASU No. 2020-06 did not have an impact on the Company’s condensed consolidated interim financial statements. (f) New accounting pronouncements not yet adopted In March 2022, the FASB issued ASU 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures (“ASU No. 2022-02”). ASU No. 2022-02 eliminates the existing troubled debt restructuring recognition and measurement guidance, and instead aligns the accounting treatment to that of other loan modifications. The amendments enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. ASU No. 2022-02 also requires that entities disclose current-period gross write-offs by year of origination for financing receivables and net investments in leases. ASU No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, and is to be adopted prospectively. The Company does not expect the adoption of ASU No. 2022-02 to have a material impact on its condensed consolidated interim financial statements. In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU No. 2022-03”). ASU No. 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered in measuring fair value. The amendments also require additional disclosures for equity securities subject to contractual sale restrictions. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, and is to be adopted prospectively. The Company does not expect the adoption of ASU No. 2022-03 to have a material impact on its condensed consolidated interim financial statements.

Inventory, net (Tables)

Inventory, net (Tables)	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory, net	Inventory, net is comprised of the following items: As of June 30, 2022 As of December 31, 2021 Raw materials $ 7,435 $ 9,211 Work-in-progress 14,548 12,405 Finished goods 16,926 10,778 Supplies and consumables 933 408 Total $ 39,842 $ 32,802

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Investments in Associates and Joint Ventures	A reconciliation of the carrying amount of the investments in equity method investees, net is as follows: Ownership interest As of June 30, 2022 As of December 31, 2021 Cronos Growing Company Inc. (“Cronos GrowCo”) 50% $ 21,731 $ 16,764 NatuEra S.à.r.l. (“Natuera”) 50% — — $ 21,731 $ 16,764 The following is a summary of the Company’s share of net income (loss) from equity method investments: For the three months ended June 30, For the six months ended June 30, 2022 2021 2022 2021 Cronos GrowCo 5,197 (459) $ 5,197 $ (758) Natuera — (656) — (2,000) $ 5,197 $ (1,115) $ 5,197 $ (2,758)
Summary of Gain on Revaluation of Other Investments	The following table summarizes the Company’s other investments activity: As of April 1, 2022 Unrealized loss Impairment charges Foreign exchange effect As of June 30, 2022 PharmaCann $ 99,154 $ — $ — $ — $ 99,154 Cronos Australia 12,607 (2,200) — (892) 9,515 $ 111,761 $ (2,200) $ — $ (892) $ 108,669 As of January 1, 2022 Unrealized gain Impairment charges Foreign exchange effect As of June 30, 2022 PharmaCann $ 110,392 $ — $ (11,238) $ — $ 99,154 Cronos Australia 8,000 1,996 — (481) 9,515 $ 118,392 $ 1,996 $ (11,238) $ (481) $ 108,669

Loans Receivable, net (Tables)

Loans Receivable, net (Tables)	6 Months Ended
	Jun. 30, 2022
Receivables [Abstract]
Schedule of Loan Receivable	Loans receivable, net consists of the following: As of June 30, 2022 As of December 31, 2021 GrowCo Facility (i) $ 3,625 $ 3,138 Add: Current portion of accrued interest 3,988 2,322 Total current portion of loans receivable 7,613 5,460 GrowCo Facility (i) 62,310 64,367 Mucci Promissory Note 14,127 14,019 Cannasoul Collaboration Loan (ii) 1,999 2,249 Total long-term portion of loans receivable 78,436 80,635 Total loans receivable, net $ 86,049 $ 86,095 (i) On August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into a senior secured credit agreement for an aggregate principal amount of C$100,000 (the “GrowCo Facility”). In August 2021, the GrowCo Facility was amended to increase the aggregate principal amount available to C$105,000. As of June 30, 2022 and December 31, 2021, Cronos GrowCo had outstanding borrowings of C$102,000 ($79,228) and C$104,000 ($81,598), respectively, from the GrowCo Facility. As of June 30, 2022, Cronos GrowCo had repaid C$2,000 ($1,554) under the terms of the GrowCo Facility. The available borrowing capacity under the GrowCo Facility was C$1,000 ($777) at June 30, 2022 and December 31, 2021. (ii) As of June 30, 2022 and December 31, 2021, Cannasoul Lab Services Ltd. has received ILS 8,297 ($2,376) and ILS 8,297 ($2,664), respectively, from the Cannasoul Collaboration Loan.
Schedule of Expected Credit Loss Allowances	Expected credit loss allowances on the Company’s long-term financial assets for the three and six months ended June 30, 2022 and 2021 were comprised of the following items: As of April 1, 2022 Increase (decrease) (i) Foreign exchange effect As of June 30, 2022 GrowCo Facility $ 14,354 $ (660) $ (401) $ 13,293 Mucci Promissory Note 93 1 (3) 91 Cannasoul Collaboration Loan 409 4 (36) 377 $ 14,856 $ (655) $ (440) $ 13,761 As of April 1, 2021 Increase (decrease) Foreign exchange effect As of June 30, 2021 GrowCo Facility $ 1,569 $ — $ 21 $ 1,590 Natuera Series A Loan (ii) 1,151 (1,153) 2 — Mucci Promissory Note 274 — 4 278 Cannasoul Collaboration Loan 26 — 13 39 $ 3,020 $ (1,153) $ 40 $ 1,907 As of January 1, 2022 Increase (decrease) (i) Foreign exchange effect As of June 30, 2022 GrowCo Facility $ 14,089 $ (664) $ (132) $ 13,293 Mucci Promissory Note 90 2 (1) 91 Cannasoul Collaboration Loan 415 7 (45) 377 $ 14,594 $ (655) $ (178) $ 13,761 As of January 1, 2021 Increase (decrease) Foreign exchange effect As of June 30, 2021 GrowCo Facility $ 1,546 $ — $ 44 $ 1,590 Natuera Series A Loan (ii) 721 (737) 16 — Mucci Promissory Note 270 — 8 278 Cannasoul Collaboration Loan 26 — 13 39 $ 2,563 $ (737) $ 81 $ 1,907 (i) During both the three and six months ended June 30, 2022, $655 was recorded as a decrease to general and administrative expenses on the condensed consolidated statements of net loss and comprehensive loss as a result of adjustments to our expected credit losses. There were no such adjustments during the three and six months ended June 30, 2021. (ii) On April 1, 2021, the Company and an affiliate of Agroidea, the other joint venture partner of Natuera, converted all advances made to Natuera under the master loan agreement entered into with Natuera on September 27, 2019, plus accrued interest, into equity of Natuera. As a result, the Company decreased its credit loss allowances by $1,153 and $737 for the three and six months ended June 30, 2021, respectively. As of June 30, 2022 and December 31, 2021, loans receivable, net for the Natuera Series A Loan was $nil.

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Definite-Lived Intangible Assets	Intangible assets, net are comprised of the following items as of June 30, 2022 and December 31, 2021: Useful life (in years) As of June 30, 2022 Cost Accumulated amortization Accumulated impairment charges Net Software 5 $ 6,065 $ (2,137) $ (80) $ 3,848 Health Canada licenses 17 8,706 (1,865) (6,841) — Ginkgo exclusive licenses (i) 10 23,655 (865) (4,668) 18,122 Israeli codes (ii) 20 294 (42) — 252 Total definite-lived intangible assets 38,720 (4,909) (11,589) 22,222 Lord Jones ® brand N/A 64,000 — (62,500) 1,500 Total intangible assets $ 102,720 $ (4,909) $ (74,089) $ 23,722 Useful life (in years) As of December 31, 2021 Cost Accumulated amortization Accumulated impairment charges Net Software 5 $ 5,644 $ (1,595) $ (4) $ 4,045 Health Canada licenses 17 8,793 (1,883) (6,910) — Ginkgo exclusive licenses 10 17,330 (335) (4,752) 12,243 Israeli codes (ii) 20 330 (39) — 291 Total definite-lived intangible assets 32,097 (3,852) (11,666) 16,579 Lord Jones ® brand N/A 64,000 — (62,500) 1,500 Trademarks N/A 142 — (142) — Total intangible assets $ 96,239 $ (3,852) $ (74,308) $ 18,079 (i) In June 2022, the Company announced the achievement of the final productivity target in respect of tetrahydrocannabivarin (“THCV”) under its collaboration and license agreement (the “Ginkgo Collaboration Agreement”) with Ginkgo Bioworks Holdings, Inc. (“Ginkgo”). As a result of the achievement of the final productivity target for THCV, the Company issued 2,201,236 common shares at a share price of C$3.47, and made a cash payment of $600, for total consideration of C$8,412 ($6,522) to Ginkgo through the Ginkgo Collaboration Agreement. The definite-lived intangible asset is being amortized using the straight-line method over its estimated useful life of ten years. (ii) The Israeli codes were transferred by non-controlling interests to Cronos Israel in exchange for their equity interests in the Cronos Israel entities.
Schedule of Indefinite-Lived Intangible Assets	Intangible assets, net are comprised of the following items as of June 30, 2022 and December 31, 2021: Useful life (in years) As of June 30, 2022 Cost Accumulated amortization Accumulated impairment charges Net Software 5 $ 6,065 $ (2,137) $ (80) $ 3,848 Health Canada licenses 17 8,706 (1,865) (6,841) — Ginkgo exclusive licenses (i) 10 23,655 (865) (4,668) 18,122 Israeli codes (ii) 20 294 (42) — 252 Total definite-lived intangible assets 38,720 (4,909) (11,589) 22,222 Lord Jones ® brand N/A 64,000 — (62,500) 1,500 Total intangible assets $ 102,720 $ (4,909) $ (74,089) $ 23,722 Useful life (in years) As of December 31, 2021 Cost Accumulated amortization Accumulated impairment charges Net Software 5 $ 5,644 $ (1,595) $ (4) $ 4,045 Health Canada licenses 17 8,793 (1,883) (6,910) — Ginkgo exclusive licenses 10 17,330 (335) (4,752) 12,243 Israeli codes (ii) 20 330 (39) — 291 Total definite-lived intangible assets 32,097 (3,852) (11,666) 16,579 Lord Jones ® brand N/A 64,000 — (62,500) 1,500 Trademarks N/A 142 — (142) — Total intangible assets $ 96,239 $ (3,852) $ (74,308) $ 18,079 (i) In June 2022, the Company announced the achievement of the final productivity target in respect of tetrahydrocannabivarin (“THCV”) under its collaboration and license agreement (the “Ginkgo Collaboration Agreement”) with Ginkgo Bioworks Holdings, Inc. (“Ginkgo”). As a result of the achievement of the final productivity target for THCV, the Company issued 2,201,236 common shares at a share price of C$3.47, and made a cash payment of $600, for total consideration of C$8,412 ($6,522) to Ginkgo through the Ginkgo Collaboration Agreement. The definite-lived intangible asset is being amortized using the straight-line method over its estimated useful life of ten years. (ii) The Israeli codes were transferred by non-controlling interests to Cronos Israel in exchange for their equity interests in the Cronos Israel entities.
Schedule of Estimated Future Amortization of Definite-Lived Intangible Assets	As of June 30, 2022, the estimated future amortization of definite-lived intangible assets is as follows: As of June 30, 2022 Remainder of 2022 (6 months) $ 1,539 2023 3,034 2024 3,016 2025 2,716 2026 2,109 2027 1,924 Thereafter 7,884 $ 22,222

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Reconciliation of Carrying Amounts	Reconciliation of the Company’s derivative liabilities activity are as follows: As of April 1, 2022 Revaluation gain Exercise of rights Foreign exchange effect As of June 30, 2022 (a) Altria Warrant $ 3,845 $ (3,245) $ — $ (109) $ 491 (b) Pre-emptive Rights 67 (49) — (2) 16 (c) Top-up Rights 187 (116) — (4) 67 $ 4,099 $ (3,410) $ — $ (115) $ 574 As of April 1, 2021 Revaluation gain Out-of-period adjustment Foreign exchange effect As of June 30, 2021 (a) Altria Warrant $ 234,656 $ (85,778) $ — $ 1,205 $ 150,083 (b) Pre-emptive Rights 20,173 (6,360) — 113 13,926 (c) Top-up Rights 17,471 (23,110) 11,278 (85) 5,554 $ 272,300 $ (115,248) $ 11,278 $ 1,233 $ 169,563 As of January 1, 2022 Revaluation gain Exercise of rights Foreign exchange effect As of June 30, 2022 (a) Altria Warrant $ 13,720 $ (13,256) $ — $ 27 $ 491 (b) Pre-emptive Rights 180 (164) — — 16 (c) Top-up Rights 475 (409) — 1 67 $ 14,375 $ (13,829) $ — $ 28 $ 574 As of January 1, 2021 Revaluation (gain)/loss Exercise of rights Foreign exchange effect As of June 30, 2021 (a) Altria Warrant $ 138,858 $ 7,186 $ — $ 4,039 $ 150,083 (b) Pre-emptive Rights 12,095 1,473 — 358 13,926 (c) Top-up Rights 12,457 (7,033) — 130 5,554 $ 163,410 $ 1,626 $ — $ 4,527 $ 169,563
Schedule of Fair Values of Derivative Liabilities	The fair values of the derivative liabilities were determined using the Black-Scholes pricing model using the following inputs: As of June 30, 2022 Altria Warrant Pre-emptive Rights Top-up Rights Share price at valuation date (per share in C$) $3.60 $3.60 $3.60 Subscription price (per share in C$) $19.00 $16.25 $16.25 Weighted-average risk-free interest rate (i) 2.74% 2.47% 2.51% Weighted-average expected life (in years) (ii) 0.69 0.45 0.63 Expected annualized volatility (iii) 77% 77% 77% Expected dividend yield —% —% —% As of December 31, 2021 Altria Warrant Pre-emptive Rights Top-up Rights Share price at valuation date (per share in C$) $4.98 $4.98 $4.98 Subscription price (per share in C$) $19.00 $16.25 $16.25 Weighted-average risk-free interest rate (i) 0.79% 0.39% 0.50% Weighted-average expected life (in years) (ii) 1.18 0.50 0.80 Expected annualized volatility (iii) 80% 80% 80% Expected dividend yield —% —% —% (i) The risk-free interest rate was based on Bank of Canada government treasury bills and bonds with a remaining term equal to the expected life of the derivative liabilities. As of June 30, 2022 and December 31, 2021, the risk-free interest rate uses a range of approximately 2.06% to 3.09% and 0.16% to 1.10%, respectively, for the Pre-emptive Rights and Top-up Rights. (ii) The expected life represents the period of time, in years, that the derivative liabilities are expected to be outstanding. The expected life of the Pre-emptive Rights and Top-up Rights is determined based on the expected term of the underlying options, warrants, and shares, to which the Pre-emptive Rights and Top-up Rights are linked. As of June 30, 2022 and December 31, 2021, the expected life uses a range of approximately 0.25 years to 3.25 years and 0.25 years to 3.75 years, respectively, for the Pre-emptive Rights and Top-up Rights. (iii) Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company.
Schedule of Sensitivity Analysis	The following table quantifies each of the significant inputs described above and provides a sensitivity analysis of the impact on the reported values of the derivative liabilities. The sensitivity analysis for each significant input is performed by assuming a 10% decrease in the input while other significant inputs remain constant at management’s best estimate as of the respective dates. While a decrease in the inputs noted below would cause a decrease in the carrying amount of the derivative liability, there would also be an equal and opposite impact on net income (loss). 10% decrease as of June 30, 2022 Altria Warrant Pre-emptive Rights Top-up Rights Share price $ 219 $ 8 $ 19 Weighted-average expected life 196 16 24 Expected annualized volatility 318 11 27 10% decrease as of December 31, 2021 Altria Warrant Pre-emptive Rights Top-up Rights Share price $ 3,970 $ 80 $ 123 Weighted-average expected life 2,971 171 133 Expected annualized volatility 5,402 96 155

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jun. 30, 2022
Restructuring and Related Activities [Abstract]
Schedule of Plan Information and Restructuring-Related Costs	The Company incurred the following restructuring costs by reportable segment: Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Rest of World $ 978 $ — $ 3,009 $ — United States 292 — 1,345 — Total $ 1,270 $ — $ 4,354 $ — The following table summarizes the Company’s restructuring activity for the three and six months ended June 30, 2022: Accrual as of April 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee termination benefits $ 1,254 $ 432 $ (798) $ 888 Other restructuring costs 144 838 (961) 21 Total $ 1,398 $ 1,270 $ (1,759) $ 909 Accrual as of January 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee termination benefits $ — $ 2,935 $ (2,047) $ 888 Other restructuring costs — 1,419 (1,398) 21 Total $ — $ 4,354 $ (3,445) $ 909

Share-based Compensation (Table

Share-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Stock-based Compensation Expense	The following table summarizes the total share-based compensation expense associated with the Company’s stock options and RSUs for the three and six months ended June 30, 2022: Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Stock options $ 1,141 $ 1,864 $ 2,870 $ 3,928 RSUs 1,475 701 3,432 1,136 Total share-based compensation $ 2,616 $ 2,565 $ 6,302 $ 5,064
Summary of the Changes in Options and Options Outstanding	The following is a summary of the changes in stock options for the six months ended June 30, 2022 and 2021: Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2022 $ 7.75 8,939,330 2.70 Exercise of options 3.11 (1,481,004) Cancellation, forfeiture and expiry of options 13.56 (89,251) Balance as of June 30, 2022 $ 8.61 7,369,075 1.53 Exercisable as of June 30, 2022 $ 8.28 4,686,991 1.04 Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2021 $ 5.40 13,755,148 2.30 Exercise of options 2.14 (5,349,818) Cancellation, forfeiture and expiry of options 14.86 (33,699) Balance as of June 30, 2021 $ 7.45 8,371,631 2.66 Exercisable as of June 30, 2021 $ 6.49 4,679,240 1.43 (i) The weighted-average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance. The following table summarizes stock options outstanding: As of June 30, 2022 As of December 31, 2021 2020 Omnibus Plan 2,900,000 2,900,000 2018 Stock Option Plan 1,492,010 1,550,074 2015 Stock Option Plan 2,977,065 4,489,256 Total stock options outstanding 7,369,075 8,939,330
Summary of Changes in RSUs	The following is a summary of the changes in RSUs for the six months ended June 30, 2022 and 2021: Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2022 $ 9.22 1,225,870 Granted (i) 4.32 4,513,992 Vested and issued 8.58 (722,721) Cancellation and forfeitures 8.32 (101,561) Balance as of June 30, 2022 $ 4.84 4,915,580 Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2021 $ 7.66 948,357 Granted (i) 11.29 515,433 Vested and issued $ 7.52 (89,912) Balance as of June 30, 2021 $ 9.03 1,373,878 (i) RSUs granted in the period vest annually in equal installments over a three-year period from the grant date or vest after a three
Summary of Changes in DSUs and Warrants	The following is a summary of the changes in DSUs for the six months ended June 30, 2022 and 2021: Financial liability Number of DSUs Balance as of January 1, 2022 $ 408 104,442 Gain on revaluation (161) — Balance as of June 30, 2022 $ 247 104,442 Financial liability Number of DSUs Balance as of January 1, 2021 $ 577 83,293 Loss on revaluation 141 — Balance as of June 30, 2021 $ 718 83,293 (e) Warrants The following is a summary of the changes in warrants for the six months ended June 30, 2021: Weighted-average exercise price (C$) Number of warrants Balance as of January 1, 2021 $ 0.25 7,987,349 Exercise of warrants 0.25 (7,987,349) Balance as of June 30, 2021 $ — —

Earnings (Loss) per Share (Tabl

Earnings (Loss) per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Earnings (Loss) Per Share	Basic and diluted earnings (loss) per share from continuing and discontinued operations are calculated as follows (in thousands, except share and per share amounts): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Basic and diluted earnings (loss) per share computation Net loss from continuing operations attributable to the shareholders of Cronos Group $ (20,221) $ (178,513) $ (52,859) $ (339,804) Weighted-average number of common shares outstanding for computation for basic and diluted earnings per share (i) 376,031,860 371,721,382 375,530,077 367,391,118 Basic loss from continuing operations per share $ (0.05) $ (0.48) $ (0.14) $ (0.92) Diluted loss per share from continuing operations $ (0.05) $ (0.48) $ (0.14) $ (0.92) Loss from discontinued operations attributable to the shareholders of Cronos Group $ — $ (561) $ — $ (582) Weighted-average number of common shares outstanding from computation for basic and diluted earnings per share 376,031,860 371,721,382 375,530,077 367,391,118 Basic earnings (loss) from discontinued operations per share $ 0.00 $ 0.00 $ 0.00 $ 0.00 Diluted earnings (loss) from discontinued operations per share $ 0.00 $ 0.00 $ 0.00 $ 0.00 (i) In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported as the inclusion of the common share equivalents would be anti-dilutive.

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Schedule of Segment Data and Adjusted EBITDA	Segment data was as follows for the three and six months ended June 30, 2022 and 2021: Three months ended June 30, 2022 United States Rest of World Corporate Total Cannabis flower $ — $ 15,739 $ — $ 15,739 Cannabis extracts 1,459 5,582 — 7,041 Other — 281 — 281 Net revenue $ 1,459 $ 21,602 $ — $ 23,061 Share of income from equity method investments $ — $ 5,197 $ — $ 5,197 Total assets $ 430,455 $ 285,902 $ 615,856 $ 1,332,213 Depreciation and amortization $ 87 $ 1,324 $ — $ 1,411 Adjusted EBITDA (3,877) (8,995) (5,927) (18,799) Three months ended June 30, 2021 United States Rest of World Corporate Total Cannabis flower $ — $ 11,597 $ — $ 11,597 Cannabis extracts 2,227 1,531 — 3,758 Other — 267 — 267 Net revenue $ 2,227 $ 13,395 $ — $ 15,622 Share of loss from equity method investments $ — $ (1,115) $ — $ (1,115) Total assets $ 473,828 $ 386,805 $ 741,850 $ 1,602,483 Depreciation and amortization 68 975 — 1,043 Adjusted EBITDA (10,711) (32,605) (6,443) (49,759) Six months ended June 30, 2022 United States Rest of World Corporate Total Cannabis flower $ — $ 34,364 $ — $ 34,364 Cannabis extracts 3,787 9,570 — 13,357 Other — 373 — 373 Net revenue $ 3,787 $ 44,307 $ — $ 48,094 Share of income from equity method investments $ — $ 5,197 $ — $ 5,197 Total assets $ 430,455 $ 285,902 $ 615,856 $ 1,332,213 Depreciation and amortization 183 2,521 — 2,704 Adjusted EBITDA (10,963) (12,420) (14,316) (37,699) Six months ended June 30, 2021 United States Rest of World Corporate Total Cannabis flower $ — $ 21,031 $ — $ 21,031 Cannabis extracts 4,668 2,234 — 6,902 Other — 300 — 300 Net revenue $ 4,668 $ 23,565 $ — $ 28,233 Share of loss from equity method investments $ — $ (2,758) $ — $ (2,758) Total assets $ 473,828 $ 386,805 $ 741,850 $ 1,602,483 Depreciation and amortization 139 1,639 — 1,778 Adjusted EBITDA (20,221) (54,789) (11,323) (86,333) The following tables set forth a reconciliation of net income (loss) as determined in accordance with U.S. GAAP to Adjusted EBITDA for the periods indicated: Three months ended June 30, 2022 United States Rest of World Corporate Total Net loss $ (4,498) $ (8,759) $ (7,081) $ (20,338) Interest income, net (426) (3,349) — (3,775) Income tax benefit — (308) — (308) Share of income from equity method investments — (5,197) — (5,197) Gain on revaluation of derivative liabilities (iii) — (3,410) — (3,410) Loss on revaluation of financial instruments (v) — 2,112 — 2,112 Foreign currency transaction loss — 2,852 — 2,852 Other, net (vii) — (2) — (2) Restructuring costs (ix) 292 978 — 1,270 Share-based compensation (x) 473 2,143 — 2,616 Financial statement review costs (xi) — — 1,154 1,154 Depreciation and amortization 282 3,945 — 4,227 Adjusted EBITDA $ (3,877) $ (8,995) $ (5,927) $ (18,799) Three months ended June 30, 2021 United States Rest of World Corporate Total Net income (loss) $ (247,847) $ 79,627 $ (11,133) $ (179,353) Interest income, net (20) (2,273) — (2,293) Share of loss from equity method investments — 1,115 — 1,115 Impairment loss on goodwill and indefinite-lived intangible assets (i) 234,914 — — 234,914 Impairment loss on long-lived assets (ii) 1,214 — — 1,214 Gain on revaluation of derivative liabilities (iii) — (115,248) — (115,248) Transaction costs (iv) — — 2,758 2,758 Gain on revaluation of financial instruments (v) — (77) — (77) Other, net (vii) — (1,050) — (1,050) Loss from discontinued operations (viii) — 561 — 561 Share-based compensation (x) 822 1,743 — 2,565 Financial statement review costs (xi) — — 1,932 1,932 Depreciation and amortization 206 2,997 — 3,203 Adjusted EBITDA $ (10,711) $ (32,605) $ (6,443) $ (49,759) Six months ended June 30, 2022 United States Rest of World Corporate Total Net loss $ (26,714) $ (6,745) $ (19,532) $ (52,991) Interest income, net (455) (5,366) — (5,821) Income tax expense — 54 — 54 Share of income from equity method investments — (5,197) — (5,197) Impairment loss on long-lived assets (ii) — 3,493 — 3,493 Gain on revaluation of derivative liabilities (iii) — (13,829) — (13,829) Gain on revaluation of financial instruments (v) — (2,156) — (2,156) Impairment loss on other investment (vi) 11,238 — — 11,238 Foreign currency transaction loss — 4,724 — 4,724 Other, net (vii) — (137) — (137) Restructuring costs (ix) 1,345 3,009 — 4,354 Share-based compensation (x) 2,909 3,393 — 6,302 Financial statement review costs (xi) — — 5,216 5,216 Depreciation and amortization 714 6,337 — 7,051 Adjusted EBITDA $ (10,963) $ (12,420) $ (14,316) $ (37,699) Six months ended June 30, 2021 United States Rest of World Corporate Total Net loss $ (259,939) $ (62,520) $ (18,519) $ (340,978) Interest income, net (23) (4,599) — (4,622) Share of loss from equity method investments — 2,758 — 2,758 Impairment loss on goodwill and indefinite-lived intangible assets (i) 234,914 — — 234,914 Impairment loss on long-lived assets (ii) 2,955 — — 2,955 Loss on revaluation of derivative liabilities (iii) — 1,626 — 1,626 Transaction costs (iv) — — 3,259 3,259 Loss on revaluation of financial instruments (v) — 123 — 123 Other, net (vii) — (1,034) — (1,034) Loss from discontinued operations (viii) — 582 — 582 Share-based compensation (x) 1,567 3,497 — 5,064 Financial statement review costs (xi) — — 3,937 3,937 Depreciation and amortization 305 4,778 — 5,083 Adjusted EBITDA $ (20,221) $ (54,789) $ (11,323) $ (86,333) (i) For the three and six months ended June 30, 2021, impairment on goodwill and indefinite-lived intangible assets relates to impairment on goodwill and indefinite-lived intangible assets related to the Company’s U.S. segment. (ii) For the six months ended June 30, 2022, impairment loss on long-lived assets related to the Company’s decision to seek a sublease for leased office space in Toronto, Ontario, Canada during the first quarter of 2022. For the three months ended June 30, 2021, impairment loss on long-lived assets relates to an impairment on property, plant and equipment in the U.S. segment. For the six months ended June 30, 2021, impairment loss on long-lived assets relates to the aforementioned impairment loss on property, plant and equipment as well as an impairment loss on leased premises in the U.S. segment from the first quarter of 2021. See Note 13 “ Impairment Loss on Long-lived Assets .” (iii) For the three and six months ended June 30, 2022 and 2021, (gain) loss on revaluation of derivative liabilities represents the fair value changes on the derivative liabilities. See Note 6 “ Derivative Liabilities .” (iv) For the three and six months ended June 30, 2021, transaction costs represent legal, financial and other advisory fees and expenses incurred in connection with various strategic investments. These costs are included in general and administrative expenses on the condensed consolidated statements of net income (loss) and comprehensive income (loss). (v) For the three and six months ended June 30, 2022, (gain) loss on revaluation of financial instruments related primarily to the Company’s equity securities in Cronos Australia. For three and six months ended June 30, 2021, (gain) loss on revaluation of financial instruments related primarily to revaluations of financial liabilities resulting from DSUs. (vi) For the six months ended June 30, 2022, impairment loss on other investments related to the PharmaCann Option for the difference between its fair value and carrying amount. See Note 3 “ Investments. ” (vii) For the three and six months ended June 30, 2022, other, net related to (gain) loss on disposal of assets. For the three and six months ended June 30, 2021, other, net primarily related to gain recorded on sale of the Company’s Winnipeg facility previously designated as held-for-sale in the first quarter of 2021. (viii) For the three and six months ended June 30, 2021, loss from discontinued operations related to the discontinuance of Original B.C. Ltd. (“OGBC”). (ix) For the three and six months ended June 30, 2022, restructuring costs related to the employee-related severance costs and other restructuring costs associated with the Realignment, including the planned exit of the Stayner Facility. See Note 7 “ Restructuring. ” (x) For the three and six months ended June 30, 2022 and 2021, share-based compensation related to the vesting expenses of share-based compensation awarded to employees under the Company’s share-based award plans as described in Note 8 “ Share-based Compensation .” (xi) For the three and six months ended June 30, 2022 and 2021, financial statement review costs include costs and reserves taken related to the restatements of the Company’s 2019 and second quarter 2021 interim financial statements, costs related to the Company’s responses to requests for information from various regulatory authorities relating to such restatements and legal costs defending shareholder class action complaints brought against the Company as a result of the 2019 restatement.
Schedule of Revenue from External Customers by Geographic Areas	Net revenue attributed to a geographic region based on the location of the customer were as follows: Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Canada $ 14,388 $ 10,664 $ 27,965 $ 18,246 Israel 7,214 2,310 16,342 4,828 United States 1,459 2,227 3,787 4,668 Other countries — 421 — 491 Net revenue $ 23,061 $ 15,622 $ 48,094 $ 28,233

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Risks and Uncertainties [Abstract]
Schedule of Fair Value of Assets Measured on Recurring Basis	The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis: June 30, 2022 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 789,543 $ — $ — $ 789,543 Short-term investments 155,352 — — 155,352 Other investments (i) 9,515 — — 9,515 Derivative liabilities — — 574 574 December 31, 2021 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 886,973 $ — $ — $ 886,973 Short-term investments 117,684 — — 117,684 Other investments (i) 8,000 — — 8,000 Derivative liabilities — — 14,375 14,375 (i) As of June 30, 2022 and December 31, 2021, the Company’s influence on Cronos Australia is deemed non-significant and the investment is considered an equity security with a readily determinable fair value. See Note 3 “ Investments ” for additional information.

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The Company incurred the following expenses for consulting services from Altria Pinnacle LLC, a subsidiary of Altria (“Altria Pinnacle”): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Altria Pinnacle - expense $ — $ 2 $ 28 $ 12 The Company made the following purchases of cannabis products from Cronos GrowCo: Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Cronos GrowCo - purchases $ 5,597 $ 534 $ 8,815 $ 534

Background, Basis of Presenta_3

Background, Basis of Presentation and Accounting Policies (Details) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) segment	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments | segment			2
Concentration Risk [Line Items]
Number of reportable segments | segment			2
Maximum exposure to credit risk			$ 1,052,494		$ 1,118,684
Net revenue, before excise taxes	$ 28,554	$ 18,848	57,960	$ 33,502
Rest of World
Concentration Risk [Line Items]
Current expected credit loss allowance on accounts receivable	2		2		8
United States
Concentration Risk [Line Items]
Current expected credit loss allowance on accounts receivable	165		$ 165		$ 104
Three Customers | Accounts Receivable | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			70%
Four Customers | Accounts Receivable | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage					88%
Three Major Customers | Rest of World
Concentration Risk [Line Items]
Net revenue, before excise taxes	$ 12,767		$ 24,690
Three Major Customers | Rest of World | Revenue Benchmark | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	56%	45%	51%
Net revenue, before excise taxes		$ 8,497
Four Major Customers | Rest of World | Revenue Benchmark | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage				54%
Net revenue, before excise taxes				$ 18,250

Inventory, net (Details)

Inventory, net (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 7,435	$ 9,211
Work-in-progress	14,548	12,405
Finished goods	16,926	10,778
Supplies and consumables	933	408
Inventory, net	$ 39,842	$ 32,802

Investments - Schedule of Inves

Investments - Schedule of Investments in Associates and Joint Ventures (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Schedule of Equity Method Investments [Line Items]
Equity method investments, net	$ 21,731		$ 21,731		$ 16,764
Share of loss from investments in equity accounted investees	$ 5,197	$ (1,115)	$ 5,197	$ (2,758)
Cronos GrowCo
Schedule of Equity Method Investments [Line Items]
Ownership interest	50%		50%
Equity method investments, net	$ 21,731		$ 21,731		16,764
Share of loss from investments in equity accounted investees	$ 5,197	(459)	$ 5,197	(758)
Natuera
Schedule of Equity Method Investments [Line Items]
Ownership interest	50%		50%
Equity method investments, net	$ 0		$ 0		$ 0
Share of loss from investments in equity accounted investees	$ 0	$ (656)	$ 0	$ (2,000)

Investments - Narrative (Detail

Investments - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Feb. 28, 2022
Variable Interest Entity [Line Items]
Impairment loss on other investments	$ 0		$ 0	$ 11,238	$ 0
PharmaCann
Variable Interest Entity [Line Items]
Impairment loss on other investments	$ 0	$ 11,238		$ 11,238
PharmaCann
Variable Interest Entity [Line Items]
Ownership interest						10.50%	6.40%
Cronos Australia
Variable Interest Entity [Line Items]
Ownership interest	10%			10%
PharmaCann
Variable Interest Entity [Line Items]
Sale of stock, number of shares issued in transaction (in shares)						473,787

Investments - Revaluation of Ot

Investments - Revaluation of Other Investments (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Other Investments [Roll Forward]
Other investments, beginning balance	$ 111,761	$ 118,392		$ 118,392
Unrealized gain (loss)	(2,200)			1,996
Impairment charges	0		$ 0	(11,238)	$ 0
Foreign exchange effect	(892)			(481)
Other investments, ending balance	108,669	111,761		108,669
PharmaCann
Other Investments [Roll Forward]
Other investments, beginning balance	99,154	110,392		110,392
Unrealized gain (loss)	0			0
Impairment charges	0	(11,238)		(11,238)
Foreign exchange effect	0			0
Other investments, ending balance	99,154	99,154		99,154
Cronos Australia
Other Investments [Roll Forward]
Other investments, beginning balance	12,607	8,000		8,000
Unrealized gain (loss)	(2,200)			1,996
Impairment charges	0			0
Foreign exchange effect	(892)			(481)
Other investments, ending balance	$ 9,515	$ 12,607		$ 9,515

Loans Receivable, net - Schedul

Loans Receivable, net - Schedule of Loan Receivable (Details) ₪ in Thousands, $ in Thousands, $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2022 CAD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 CAD ($)	Jun. 30, 2022 CAD ($)	Jun. 30, 2022 ILS (₪)	Dec. 31, 2021 CAD ($)	Dec. 31, 2021 ILS (₪)	Aug. 31, 2021 USD ($)	Aug. 23, 2019 USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total current portion of loans receivable	$ 7,613		$ 5,460
Total long-term portion of loans receivable	78,436		80,635
Total loans receivable, net	86,049		86,095
Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Add: Current portion of accrued interest	3,988		2,322
GrowCo Facility | Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current portion of loans receivable, before accrued interest	3,625		3,138
Long term portion of loans receivable, before accrued interest	62,310		64,367
Face amount									$ 105,000	$ 100,000
Draw downs	79,228	$ 102,000	81,598	$ 104,000
(Advances) repayments on loan receivables	1,554	$ 2,000
Available borrowing capacity	777		777		$ 1,000		$ 1,000
Mucci Promissory Note | Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long term portion of loans receivable, before accrued interest	14,127		14,019
Cannasoul Collaboration Loan | Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long term portion of loans receivable, before accrued interest	1,999		2,249
Cannasoul Collaboration Loan | Loans Receivable | Establishment of a Commercial Cannabis Analytical Testing Laboratory | Cannasoul | Variable Interest Entity, Not Primary Beneficiary
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collaborative arrangement, installment received	$ 2,376		$ 2,664			₪ 8,297		₪ 8,297

Loans Receivable, net - Sched_2

Loans Receivable, net - Schedule of Expected Credit Loss Allowances (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	$ 14,856,000	$ 3,020,000	$ 14,594,000	$ 2,563,000
Increase (decrease)	(655,000)	(1,153,000)	(655,000)	(737,000)
Foreign exchange effect	(440,000)	40,000	(178,000)	81,000
Ending balance	13,761,000	1,907,000	13,761,000	1,907,000
Financing receivable, credit loss, expense, including transferred into investment	(655,000)	(1,153,000)	(655,000)	(737,000)
GrowCo Facility | Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	14,354,000	1,569,000	14,089,000	1,546,000
Increase (decrease)	(660,000)	0	(664,000)	0
Foreign exchange effect	(401,000)	21,000	(132,000)	44,000
Ending balance	13,293,000	1,590,000	13,293,000	1,590,000
Natuera Series A Loan | Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance		1,151,000	0	721,000
Increase (decrease)		(1,153,000)		(737,000)
Foreign exchange effect		2,000		16,000
Ending balance	0	0	0	0
Mucci Promissory Note | Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	93,000	274,000	90,000	270,000
Increase (decrease)	1,000	0	2,000	0
Foreign exchange effect	(3,000)	4,000	(1,000)	8,000
Ending balance	91,000	278,000	91,000	278,000
Cannasoul Collaboration Loan | Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	409,000	26,000	415,000	26,000
Increase (decrease)	4,000	0	7,000	0
Foreign exchange effect	(36,000)	13,000	(45,000)	13,000
Ending balance	$ 377,000	$ 39,000	$ 377,000	$ 39,000

Intangible Assets, net - Schedu

Intangible Assets, net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Cost	$ 38,720	$ 38,720	$ 32,097
Accumulated amortization	(4,909)	(4,909)	(3,852)
Accumulated impairment charges	(11,589)	(11,589)	(11,666)
Net	22,222	22,222	16,579
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Cost	102,720	102,720	96,239
Accumulated amortization	(4,909)	(4,909)	(3,852)
Accumulated impairment charges	(74,089)	(74,089)	(74,308)
Intangible assets, net	23,722	23,722	18,079
Lord Jones brand
Indefinite-lived Intangible Assets [Line Items]
Cost	64,000	64,000	64,000
Accumulated impairment charges	(62,500)	(62,500)	(62,500)
Net	1,500	$ 1,500	1,500
Trademarks
Indefinite-lived Intangible Assets [Line Items]
Cost			142
Accumulated impairment charges			(142)
Net			$ 0
Software
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)		5 years	5 years
Cost	6,065	$ 6,065	$ 5,644
Accumulated amortization	(2,137)	(2,137)	(1,595)
Accumulated impairment charges	(80)	(80)	(4)
Net	3,848	3,848	4,045
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated amortization	(2,137)	$ (2,137)	$ (1,595)
Health Canada licenses
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)		17 years	17 years
Cost	8,706	$ 8,706	$ 8,793
Accumulated amortization	(1,865)	(1,865)	(1,883)
Accumulated impairment charges	(6,841)	(6,841)	(6,910)
Net	0	0	0
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated amortization	$ (1,865)	$ (1,865)	$ (1,883)
Ginkgo exclusive licenses
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	10 years	10 years	10 years
Cost	$ 23,655	$ 23,655	$ 17,330
Accumulated amortization	(865)	(865)	(335)
Accumulated impairment charges	(4,668)	(4,668)	(4,752)
Net	18,122	18,122	12,243
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated amortization	(865)	$ (865)	$ (335)
Israeli codes
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)		20 years	20 years
Cost	294	$ 294	$ 330
Accumulated amortization	(42)	(42)	(39)
Net	252	252	291
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated amortization	$ (42)	$ (42)	$ (39)

Intangible Assets, net - Sche_2

Intangible Assets, net - Schedule of Intangible Assets Footnote (Details) $ / shares in Units, $ in Thousands, $ in Thousands	1 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022 USD ($) shares	Jun. 30, 2022 CAD ($) $ / shares shares	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Purchase of intangible assets			$ 421	$ 843
Ginkgo exclusive licenses
Finite-Lived Intangible Assets [Line Items]
Sale of stock, price per share (in dollars per share) | $ / shares		$ 3.47
Shares issued	$ 6,522	$ 8,412
Purchase of intangible assets	$ 600
Useful life	10 years	10 years	10 years		10 years
Common Shares | Ginkgo exclusive licenses
Finite-Lived Intangible Assets [Line Items]
Shares issued (in shares) | shares	2,201,236	2,201,236

Intangible Assets, net - Narrat

Intangible Assets, net - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 606	$ 274	$ 1,121	$ 443
Impairment of intangible assets, indefinite-lived (excluding goodwill)	$ 0		$ 0
Lord Jones brand
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets, indefinite-lived (excluding goodwill)		$ 56,500		$ 56,500

Intangible Assets, net - Sche_3

Intangible Assets, net - Schedule of Estimated Future Amortization of Definite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2022 (6 months)	$ 1,539
2023	3,034
2024	3,016
2025	2,716
2026	2,109
2027	1,924
Thereafter	7,884
Net	$ 22,222	$ 16,579

Derivative Liabilities - Narrat

Derivative Liabilities - Narrative (Details)	6 Months Ended
	Jun. 30, 2022 warrant $ / shares shares	Dec. 31, 2021 shares	Mar. 08, 2019
Derivative [Line Items]
Common stock, shares issued (in shares)	377,896,371	374,952,693
Altria Warrant
Derivative [Line Items]
Number of warrants issued | warrant	1
Exercise price (in dollars per share) | $ / shares	$ 19
Altria Investment
Derivative [Line Items]
Maximum additional subscription percentage	10%
Derivative liability, additional subscription (in shares)	83,976,971
Pre-emptive Rights
Derivative [Line Items]
Exercise price (in dollars per share) | $ / shares	$ 16.25
Exercise rights, minimum ownership percentage	20%
Altria Group, Inc. | Cronos Group, Inc.
Derivative [Line Items]
Ownership percentage, if warrant exercised	52%
Altria Group, Inc. | Cronos Group, Inc.
Derivative [Line Items]
Common stock, shares issued (in shares)	156,573,537
Ownership percentage (Whistler - less than)	41%		45%

Derivative Liabilities - Schedu

Derivative Liabilities - Schedule of Reconciliation of Carrying Amounts (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Derivative Instruments [Roll Forward]
Beginning balance	$ 4,099	$ 272,300	$ 14,375	$ 163,410
Revaluation (gain)/loss	(3,410)	(115,248)	(13,829)	1,626
Exercise of rights	0		0	0
Out-of-period adjustment		11,278
Foreign exchange effect	(115)	1,233	28	4,527
Ending balance	574	169,563	574	169,563
Altria Warrant
Derivative Instruments [Roll Forward]
Beginning balance	3,845	234,656	13,720	138,858
Revaluation (gain)/loss	(3,245)	(85,778)	(13,256)	7,186
Exercise of rights	0		0	0
Out-of-period adjustment		0
Foreign exchange effect	(109)	1,205	27	4,039
Ending balance	491	150,083	491	150,083
Pre-emptive Rights
Derivative Instruments [Roll Forward]
Beginning balance	67	20,173	180	12,095
Revaluation (gain)/loss	(49)	(6,360)	(164)	1,473
Exercise of rights	0		0	0
Out-of-period adjustment		0
Foreign exchange effect	(2)	113	0	358
Ending balance	16	13,926	16	13,926
Top-up Rights
Derivative Instruments [Roll Forward]
Beginning balance	187	17,471	475	12,457
Revaluation (gain)/loss	(116)	(23,110)	(409)	(7,033)
Exercise of rights	0		0	0
Out-of-period adjustment		11,278
Foreign exchange effect	(4)	(85)	1	130
Ending balance	$ 67	$ 5,554	$ 67	$ 5,554

Derivative Liabilities - Sche_2

Derivative Liabilities - Schedule of Fair Values of Derivative Liabilities (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2022 $ / shares	Dec. 31, 2021 $ / shares
Altria Warrant | Share price at valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	3.60	4.98
Altria Warrant | Subscription price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	19	19
Altria Warrant | Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.77	0.80
Altria Warrant | Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Altria Warrant | Weighted Average | Weighted-average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0274	0.0079
Altria Warrant | Weighted Average | Weight-average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	8 months 8 days	1 year 2 months 4 days
Pre-emptive Rights | Share price at valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	3.60	4.98
Pre-emptive Rights | Subscription price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	16.25	16.25
Pre-emptive Rights | Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.77	0.80
Pre-emptive Rights | Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Pre-emptive Rights | Weighted Average | Weighted-average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0247	0.0039
Pre-emptive Rights | Weighted Average | Weight-average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	5 months 12 days	6 months
Top-up Rights | Share price at valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	3.60	4.98
Top-up Rights | Subscription price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	16.25	16.25
Top-up Rights | Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.77	0.80
Top-up Rights | Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Top-up Rights | Weighted Average | Weighted-average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0251	0.0050
Top-up Rights | Weighted Average | Weight-average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	7 months 17 days	9 months 18 days
Pre-emptive Rights and Top-up Rights | Minimum | Weighted-average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0206	0.0016
Pre-emptive Rights and Top-up Rights | Minimum | Weight-average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	3 months	3 months
Pre-emptive Rights and Top-up Rights | Maximum | Weighted-average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0309	0.0110
Pre-emptive Rights and Top-up Rights | Maximum | Weight-average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	3 years 3 months	3 years 9 months

Derivative Liabilities - Sche_3

Derivative Liabilities - Schedule of Sensitivity Analysis (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Altria Warrant
Sensitivity Analysis, Impact of 10 Percent Decrease (Increase) on Net Income (Loss) [Abstract]
Share price	$ 219	$ 3,970
Weighted-average expected life	196	2,971
Expected annualized volatility	318	5,402
Pre-emptive Rights
Sensitivity Analysis, Impact of 10 Percent Decrease (Increase) on Net Income (Loss) [Abstract]
Share price	8	80
Weighted-average expected life	16	171
Expected annualized volatility	11	96
Top-up Rights
Sensitivity Analysis, Impact of 10 Percent Decrease (Increase) on Net Income (Loss) [Abstract]
Share price	19	123
Weighted-average expected life	24	133
Expected annualized volatility	$ 27	$ 155

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - Realignment - USD ($) $ in Thousands	Jun. 30, 2022	Feb. 28, 2022
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges		$ 6,400
Restructuring costs incurred to date	$ 4,354
Facility Closing
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 2,000

Restructuring - Costs by Segmen

Restructuring - Costs by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 1,270	$ 0	$ 4,354	$ 0
Realignment
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1,270	0	4,354	0
Rest of World | Realignment
Restructuring Cost and Reserve [Line Items]
Restructuring costs	978	0	3,009	0
United States | Realignment
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 292	$ 0	$ 1,345	$ 0

Restructuring - Restructuring A

Restructuring - Restructuring Activity (Details) - Realignment - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Restructuring Reserve [Roll Forward]
Accrual, Beginning Balance	$ 1,398	$ 0
Expenses	1,270	4,354
Payments/Write-offs	(1,759)	(3,445)
Accrual, Ending Balance	909	909
Employee termination benefits
Restructuring Reserve [Roll Forward]
Accrual, Beginning Balance	1,254	0
Expenses	432	2,935
Payments/Write-offs	(798)	(2,047)
Accrual, Ending Balance	888	888
Other restructuring costs
Restructuring Reserve [Roll Forward]
Accrual, Beginning Balance	144	0
Expenses	838	1,419
Payments/Write-offs	(961)	(1,398)
Accrual, Ending Balance	$ 21	$ 21

Share-based Compensation - Summ

Share-based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 2,616	$ 2,565	$ 6,302	$ 5,064
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	1,141	1,864	2,870	3,928
Restricted share units
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 1,475	$ 701	$ 3,432	$ 1,136

Share-based Compensation - Stoc

Share-based Compensation - Stock Options Narrative (Details) - Stock options	6 Months Ended
	Jun. 30, 2022
2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
Prior Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	7 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years

Share-based Compensation - Su_2

Share-based Compensation - Summary of the Changes in Options (Details) - $ / shares	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Weighted average exercise price
Balance at beginning of period (in dollars per share)	$ 7.75	$ 5.40	$ 5.40
Exercise of options (in dollars per share)	3.11	2.14
Cancellation, forfeiture and expiry of options (in dollars per share)	13.56	14.86
Balance at end of period (in dollars per share)	8.61	7.45	$ 7.75	$ 5.40
Weighted average exercise price of options exercisable (in dollars per share)	$ 8.28	$ 6.49
Number of options
Balance at beginning of period (in shares)	8,939,330	13,755,148	13,755,148
Exercise of options (in shares)	(1,481,004)	(5,349,818)
Cancellation, forfeiture and expiry of options (in shares)	(89,251)	(33,699)
Balance at end of period (in shares)	7,369,075	8,371,631	8,939,330	13,755,148
Exercisable (in shares)	4,686,991	4,679,240
Weighted-average remaining contractual term (years)
Outstanding	1 year 6 months 10 days	2 years 7 months 28 days	2 years 8 months 12 days	2 years 3 months 18 days
Exercisable	1 year 14 days	1 year 5 months 4 days

Share-based Compensation - Sche

Share-based Compensation - Schedule of Stock Options Outstanding (Details) - shares	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	7,369,075	8,939,330	8,371,631	13,755,148
2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	2,900,000	2,900,000
2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	1,492,010	1,550,074
2015 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	2,977,065	4,489,256

Share-based Compensation - Su_3

Share-based Compensation - Summary of Changes in RSUs (Details) - Restricted share units - $ / shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Weighted-average grant date fair value
Balance at beginning of period (in dollars per share)	$ 9.22	$ 7.66
Granted (in dollars per share)	4.32	11.29
Vested and issued (in dollars per share)	8.58	7.52
Cancellation and forfeitures (in dollars per share)	8.32
Balance at end of period (in dollars per share)	$ 4.84	$ 9.03
Number of awards
Balance at beginning of period (in shares)	1,225,870	948,357
Granted (in shares)	4,513,992	515,433
Vested and issued/liabilities settled (in shares)	(722,721)	(89,912)
Cancellation and forfeitures (in shares)	(101,561)
Balance at end of period (in shares)	4,915,580	1,373,878
Vesting period	3 years
Minimum
Number of awards
Cliff period	3 years
Maximum
Number of awards
Cliff period	5 years

Share-based Compensation - Su_4

Share-based Compensation - Summary of DSU Activity (Details) - Deferred Share Units (DSUs) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Financial liability
Balance at beginning of period	$ 408	$ 577
(Gain) loss on revaluation	(161)	141
Balance at end of period	$ 247	$ 718
Number of awards
Balance at beginning of period (in shares)	104,442	83,293
Balance at end of period (in shares)	104,442	83,293

Share-based Compensation - Su_5

Share-based Compensation - Summary of Changes in Warrants (Details) - Warrants	6 Months Ended
	Jun. 30, 2021 $ / shares shares
Weighted-average exercise price (C$)
Balance at beginning of period (in dollars per share) | $ / shares	$ 0.25
Exercise of warrants (in dollars per share) | $ / shares	0.25
Balance at end of period (in dollars per share) | $ / shares	$ 0
Number of awards
Balance at beginning of period (in shares) | shares	7,987,349
Exercise of warrants (in shares) | shares	(7,987,349)
Balance at end of period (in shares) | shares	0

Earnings (Loss) per Share - Sch

Earnings (Loss) per Share - Schedule of Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Basic and diluted earnings (loss) per share computation
Net loss from continuing operations attributable to the shareholders of Cronos Group	$ (20,221)	$ (178,513)	$ (52,859)	$ (339,804)
Weighted-average number of common shares outstanding for computation for basic earnings per share (in shares)	376,031,860	371,721,382	375,530,077	367,391,118
Weighted-average number of common shares outstanding for computation for diluted earnings per share (in shares)	376,031,860	371,721,382	375,530,077	367,391,118
Basic loss from continuing operations per share (in dollars per share)	$ (0.05)	$ (0.48)	$ (0.14)	$ (0.92)
Diluted loss per share from continuing operations (in dollars per share)	$ (0.05)	$ (0.48)	$ (0.14)	$ (0.92)
Loss from discontinued operations attributable to the shareholders of Cronos Group	$ 0	$ (561)	$ 0	$ (582)
Basic loss from discontinued operations per share (in dollars per share)	$ 0	$ 0	$ 0	$ 0
Diluted loss from discontinued operations per share (in dollars per share)	$ 0	$ 0	$ 0	$ 0
Total anti-dilutive securities (in shares)	119,589,123	120,491,183	118,906,603	128,373,444

Segment Information - Schedule

Segment Information - Schedule of Segment Data (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Segment Reporting Information [Line Items]
Net revenue	$ 23,061	$ 15,622	$ 48,094	$ 28,233
Share of income (loss) from equity method investments	5,197	(1,115)	5,197	(2,758)
Total assets	1,332,213	1,602,483	1,332,213	1,602,483	$ 1,397,738
Depreciation and amortization	1,411	1,043	2,704	1,778
Adjusted EBITDA	(18,799)	(49,759)	(37,699)	(86,333)
Operating Segments | United States
Segment Reporting Information [Line Items]
Net revenue	1,459	2,227	3,787	4,668
Share of income (loss) from equity method investments	0	0	0	0
Total assets	430,455	473,828	430,455	473,828
Depreciation and amortization	87	68	183	139
Adjusted EBITDA	(3,877)	(10,711)	(10,963)	(20,221)
Operating Segments | Rest of World
Segment Reporting Information [Line Items]
Net revenue	21,602	13,395	44,307	23,565
Share of income (loss) from equity method investments	5,197	(1,115)	5,197	(2,758)
Total assets	285,902	386,805	285,902	386,805
Depreciation and amortization	1,324	975	2,521	1,639
Adjusted EBITDA	(8,995)	(32,605)	(12,420)	(54,789)
Corporate
Segment Reporting Information [Line Items]
Net revenue	0	0	0	0
Share of income (loss) from equity method investments	0	0	0	0
Total assets	615,856	741,850	615,856	741,850
Depreciation and amortization	0	0	0	0
Adjusted EBITDA	(5,927)	(6,443)	(14,316)	(11,323)
Cannabis flower
Segment Reporting Information [Line Items]
Net revenue	15,739	11,597	34,364	21,031
Cannabis flower | Operating Segments | United States
Segment Reporting Information [Line Items]
Net revenue	0	0	0	0
Cannabis flower | Operating Segments | Rest of World
Segment Reporting Information [Line Items]
Net revenue	15,739	11,597	34,364	21,031
Cannabis flower | Corporate
Segment Reporting Information [Line Items]
Net revenue	0	0	0	0
Cannabis extracts
Segment Reporting Information [Line Items]
Net revenue	7,041	3,758	13,357	6,902
Cannabis extracts | Operating Segments | United States
Segment Reporting Information [Line Items]
Net revenue	1,459	2,227	3,787	4,668
Cannabis extracts | Operating Segments | Rest of World
Segment Reporting Information [Line Items]
Net revenue	5,582	1,531	9,570	2,234
Cannabis extracts | Corporate
Segment Reporting Information [Line Items]
Net revenue	0	0	0	0
Other
Segment Reporting Information [Line Items]
Net revenue	281	267	373	300
Other | Operating Segments | United States
Segment Reporting Information [Line Items]
Net revenue	0	0	0	0
Other | Operating Segments | Rest of World
Segment Reporting Information [Line Items]
Net revenue	281	267	373	300
Other | Corporate
Segment Reporting Information [Line Items]
Net revenue	$ 0	$ 0	$ 0	$ 0

Segment Information - Schedul_2

Segment Information - Schedule of Adjusted EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Net income (loss)	$ (20,338)	$ (32,653)	$ (179,353)	$ (161,625)	$ (52,991)	$ (340,978)
Interest income, net	(3,775)		(2,293)		(5,821)	(4,622)
Income tax expense (benefit)	(308)		0		54	0
Share of income (loss) from equity method investments	(5,197)		1,115		(5,197)	2,758
Impairment loss on goodwill and indefinite-lived intangible assets	0		234,914		0	234,914
Impairment loss on long-lived assets	0		1,214		3,493	2,955
(Gain) loss on revaluation of derivative liabilities	3,410		115,248		13,829	(1,626)
Transaction costs			2,758			3,259
(Gain) loss on revaluation of financial instruments	2,112		(77)		(2,156)	123
Impairment loss on other investments	0		0		11,238	0
Foreign currency transaction loss	2,852		0		4,724	0
Other, net	(2)		(1,050)		(137)	(1,034)
Restructuring costs	1,270		0		4,354	0
Loss from discontinued operations	0		561		0	582
Share-based compensation	2,616		2,565		6,302	5,064
Financial statement review costs	1,154		1,932		5,216	3,937
Depreciation and amortization	4,227		3,203		7,051	5,083
Adjusted EBITDA	(18,799)		(49,759)		(37,699)	(86,333)
Operating Segments | United States
Segment Reporting Information [Line Items]
Net income (loss)	(4,498)		(247,847)		(26,714)	(259,939)
Interest income, net	(426)		(20)		(455)	(23)
Income tax expense (benefit)	0				0
Share of income (loss) from equity method investments	0		0		0	0
Impairment loss on goodwill and indefinite-lived intangible assets			234,914			234,914
Impairment loss on long-lived assets			1,214		0	2,955
(Gain) loss on revaluation of derivative liabilities	0		0		0	0
Transaction costs			0			0
(Gain) loss on revaluation of financial instruments	0		0		0	0
Impairment loss on other investments					11,238
Foreign currency transaction loss	0				0
Other, net	0		0		0	0
Restructuring costs	292				1,345
Loss from discontinued operations			0			0
Share-based compensation	473		822		2,909	1,567
Financial statement review costs	0		0		0	0
Depreciation and amortization	282		206		714	305
Adjusted EBITDA	(3,877)		(10,711)		(10,963)	(20,221)
Operating Segments | Rest of World
Segment Reporting Information [Line Items]
Net income (loss)	(8,759)		79,627		(6,745)	(62,520)
Interest income, net	(3,349)		(2,273)		(5,366)	(4,599)
Income tax expense (benefit)	(308)				54
Share of income (loss) from equity method investments	(5,197)		1,115		(5,197)	2,758
Impairment loss on goodwill and indefinite-lived intangible assets			0			0
Impairment loss on long-lived assets			0		3,493	0
(Gain) loss on revaluation of derivative liabilities	3,410		115,248		13,829	(1,626)
Transaction costs			0			0
(Gain) loss on revaluation of financial instruments	2,112		(77)		(2,156)	123
Impairment loss on other investments					0
Foreign currency transaction loss	2,852				4,724
Other, net	(2)		(1,050)		(137)	(1,034)
Restructuring costs	978				3,009
Loss from discontinued operations			561			582
Share-based compensation	2,143		1,743		3,393	3,497
Financial statement review costs	0		0		0	0
Depreciation and amortization	3,945		2,997		6,337	4,778
Adjusted EBITDA	(8,995)		(32,605)		(12,420)	(54,789)
Corporate
Segment Reporting Information [Line Items]
Net income (loss)	(7,081)		(11,133)		(19,532)	(18,519)
Interest income, net	0		0		0	0
Income tax expense (benefit)	0				0
Share of income (loss) from equity method investments	0		0		0	0
Impairment loss on goodwill and indefinite-lived intangible assets			0			0
Impairment loss on long-lived assets			0		0	0
(Gain) loss on revaluation of derivative liabilities	0		0		0	0
Transaction costs			2,758			3,259
(Gain) loss on revaluation of financial instruments	0		0		0	0
Impairment loss on other investments					0
Foreign currency transaction loss	0				0
Other, net	0		0		0	0
Restructuring costs	0				0
Loss from discontinued operations			0			0
Share-based compensation	0		0		0	0
Financial statement review costs	1,154		1,932		5,216	3,937
Depreciation and amortization	0		0		0	0
Adjusted EBITDA	$ (5,927)		$ (6,443)		$ (14,316)	$ (11,323)

Segment Information - Schedul_3

Segment Information - Schedule of Revenue from External Customers by Geographic Areas (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	$ 23,061	$ 15,622	$ 48,094	$ 28,233
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	14,388	10,664	27,965	18,246
Israel
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	7,214	2,310	16,342	4,828
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	1,459	2,227	3,787	4,668
Other countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	$ 0	$ 421	$ 0	$ 491

Commitments and Contingencies (

Commitments and Contingencies (Details) - Pending Litigation $ in Millions	Jun. 16, 2020 CAD ($)	Mar. 12, 2020 shareholder complaint
Litigation Relating to Marketing, Distribution and Sale of Products
Loss Contingencies [Line Items]
Damages sought	$ 500
Punitive damages sought	$ 5
U.S. District Court of Eastern District of New York Vs. Cronos
Loss Contingencies [Line Items]
Number of alleged shareholders | shareholder		2
Number of putative class action complaints | complaint		2

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Assets Measured on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 789,543	$ 886,973
Short-term investments	155,352	117,684
Other investments	9,515	8,000
Derivative liabilities	574	14,375
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	789,543	886,973
Short-term investments	155,352	117,684
Other investments	9,515	8,000
Derivative liabilities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments	0	0
Other investments	0	0
Derivative liabilities	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments	0	0
Other investments	0	0
Derivative liabilities	$ 574	$ 14,375

Impairment Loss on Long-lived_2

Impairment Loss on Long-lived Assets (Details) ft² in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) ft²	Jun. 30, 2021 USD ($) ft²
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment charge related to right-of-use lease asset			$ 1,986
Lease impairment, area of land (in sq ft) | ft²			29	6
Impairment loss on long-lived assets	$ 0	$ 1,214	$ 3,493	$ 2,955
Impairment charge on the de-recognition of the right-of-use asset				702
Operating Segments | United States
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment loss on long-lived assets		1,214	0	2,955
Leasehold improvements
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment loss on long-lived assets			$ 1,507	1,039
Property, Plant and Equipment Associated with Sales Channels | Operating Segments | United States
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment loss on long-lived assets		$ 1,214		$ 1,214

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Mar. 08, 2019
Consulting Services Arrangement | Altria Pinnacle
Related Party Transaction [Line Items]
Consulting fees	$ 0	$ 2,000	$ 28,000	$ 12,000
Amounts payable	0		0		$ 0
Cannabis Purchases | Cronos GrowCo
Related Party Transaction [Line Items]
Amounts payable	2,103,000		2,103,000		$ 82,000
Purchases	$ 5,597,000	$ 534,000	$ 8,815,000	$ 534,000
Cronos Group, Inc. | Altria Group, Inc.
Related Party Transaction [Line Items]
Ownership interest	41%		41%			45%
Cronos GrowCo
Related Party Transaction [Line Items]
Ownership interest	50%		50%